crxm-10q_20150930.htm

0001564590-16-026389.txt : 20161027 0001564590-16-026389.hdr.sgml : 20161027 20161027164338 ACCESSION NUMBER: 0001564590-16-026389 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20161027 DATE AS OF CHANGE: 20161027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Taxus Cardium Pharmaceuticals Group Inc. CENTRAL INDEX KEY: 0000772320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840635673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33635 FILM NUMBER: 161956029 BUSINESS ADDRESS: STREET 1: 11750 SORRENTO VALLEY ROAD STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 436-1000 MAIL ADDRESS: STREET 1: 11750 SORRENTO VALLEY ROAD STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Cardium Therapeutics, Inc. DATE OF NAME CHANGE: 20060118 FORMER COMPANY: FORMER CONFORMED NAME: Cadium Therapeutics, Inc. DATE OF NAME CHANGE: 20060118 FORMER COMPANY: FORMER CONFORMED NAME: CARDIUM THERAPEUTICS, INC DATE OF NAME CHANGE: 20060118 10-Q 1 crxm-10q_20150930.htm 10-Q crxm-10q_20150930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-33635

TAXUS CARDIUM PHARMACEUTICALS GROUP INC.

(Exact name of registrant as specified in its charter)

Delaware	27-0075787
(State of incorporation)	(IRS Employer Identification No.)

11568 Sorrento Valley Rd, Suite #14 San Diego, California 92121	(858) 436-1000
(Address of principal executive offices)	(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒

As of October 27, 2016, the registrant had 13,623,544 shares of common stock outstanding.

TABLE OF CONTENTS

		Page

EXPLANATORY NOTE		1

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS		1

PART 1 FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)

	Condensed Consolidated Balance Sheets	3

	Condensed Consolidated Statements of Operations	4

	Condensed Consolidated Statements of Cash Flows	5

	Notes to Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II OTHER INFORMATION

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 3	Defaults Upon Senior Securities	29

Item 4.	Mine Safety Disclosures	29

Item 5.	Other Information	29

Item 6.	Exhibits	30

SIGNATURES		31

EXPLANATORY NOTE

Unless the context requires otherwise, all references in this report to the “Company,” “Taxus Cardium,” “Cardium,” “we,” “our,” and “us” refer to Taxus Cardium Pharmaceuticals Group Inc. and, as applicable, our consolidated subsidiaries; Angionetics, Inc. (“Angionetics’), Activation Therapeutics, Inc. (“Activation Therapeutics”) and LifeAgain Insurance Solutions, Inc. (“LifeAgain”).

Based on financial hardship, we were unable to secure the necessary accounting review and audit of our financial statements and suspended filing of our regular quarterly and annual reports following our Quarterly Report on Form 10-Q for the period ended June 30, 2015. We are filing this Quarterly Report on Form 10-Q for the period ended September 30, 2015. We are in the process of preparing our Annual Report for the year ended December 31, 2015 and expect to file that report in the fourth quarter 2016. It is our intention to become current in our reporting obligations under the Securities Exchange Act of 1934, as amended. In the meantime, we have included disclosure concerning our more recent operations in Note 7—Subsequent Events in the footnotes to the condensed consolidated financial statements included with this report.

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

Certain statements in this report, including information incorporated by reference, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. Words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “believes,” “anticipates,” “intends,” “estimates,” “approximates,” “predicts,” or “projects,” or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results and the development of our products, are forward-looking statements. Forward-looking statements in this report may include statements about:

•

our ability to fund operations and business plans, and the timing of any funding or corporate development transactions we may pursue;

•

planned development pathways and potential commercialization activities or opportunities;

•

the timing, conduct and outcome of discussions with regulatory agencies, regulatory submissions and clinical trials, including the timing for completion of clinical studies;

•

our ability to realize revenues, raise sufficient financing, maintain stock price and valuation, and to regain the listing of our common stock on a national exchange;

•

our beliefs and opinions about the safety and efficacy of our products and product candidates and the anticipated results of our clinical studies and trials;

•

our ability to enter into acceptable relationships with one or more contract manufacturers or other service providers on which we may depend, and the ability of such contract manufacturers or other service providers to manufacture biologics, devices, or other key products or components, or to provide other services, of an acceptable quality on a timely and cost-effective basis;

•

our ability to enter into acceptable relationships with one or more development or commercialization partners to advance the commercialization of new products and product candidates and the timing of any product launches;

•

our growth, expansion and acquisition strategies, the success of such strategies, and the benefits we believe can be derived from such strategies;

•

our ability to pursue and effectively develop new product opportunities and acquisitions and to obtain value from such product opportunities and acquisitions;

•

the protection expected from our intellectual property rights and those of others, including actual or potential competitors;

•

the outcome of litigation matters;

•

the anticipated activities of our personnel, consultants and collaborators;

•

expectations concerning results of our clinical studies or other operations outside the United States;

•

current and future economic and political conditions;

•

overall industry and market performance;

•

the impact of new accounting pronouncements;

•

management’s goals and plans for future operations; and

•

other assumptions described in this report underlying or relating to any forward-looking statements.

The forward-looking statements in this report speak only as of the date of this report and caution should be taken not to place undue reliance on any such forward-looking statements. Forward-looking statements are subject to certain events, risks, and uncertainties that may be outside of our control. When considering forward-looking statements, you should carefully review the risks, uncertainties and other cautionary statements in this report as they identify certain important factors that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include, among others, the risks described under Item 1A and elsewhere in this report, as well as in other reports and documents we file with the United States Securities and Exchange Commission (the “SEC”).

TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited)

	September 30,			December 31,
	2015			2014
Assets
Current assets:
Cash and cash equivalents	$	18,217		$	216,733
Prepaid expenses and other assets		19,828			202,957
Total current assets		38,045			419,690
Property and equipment, net		8,738			16,414
Investments		—			300,000
Other long-term assets		—			9,989
Total assets	$	46,783		$	746,093
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	1,621,284		$	1,204,302
Accrued liabilities		967,916			535,251
Advances from related party – officer (net)		819,251			688,433
Total current liabilities		3,408,451			2,427,986
Total liabilities		3,408,451			2,427,986
Commitments and contingencies
Stockholders’ deficit:
Subscribed shares issuable – common stock		600,000			—
Series A Convertible Preferred stock, $0.0001 par value; 40,000,000 shares authorized; issued and outstanding 1,116 at September 30, 2015 and 1,176 at December 31, 2014, with liquidation preferences of $1,000		—			—
Common stock, $0.0001 par value; 200,000,000 shares authorized; issued and outstanding 12,975,044 at September 30, 2015 and 12,775,044 at December 31, 2014,		1,298			1,278
Additional paid-in capital		110,739,887			109,150,983
Accumulated deficit		(114,702,853	)		(110,834,154	)
Total stockholders’ deficit		(3,361,668	)		(1,681,893	)
Total liabilities and stockholders’ deficit	$	46,783		$	746,093

See accompanying notes, which are an integral part of these condensed consolidated financial statements.

TAXUS CARDIUM PHARMACEUTICALS GROUP INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Operating expenses
Research and development	$	108,671		$	126,788		$	486,759		$	508,940
Selling, general and administrative		1,081,189			586,414			2,449,745			2,580,009
Total operating expenses		1,189,860			713,202			2,936,504			3,088,949
Loss from operations		(1,189,860	)		(713,202	)		(2,936,504	)		(3,088,949	)
Interest expense		(2,106	)		(28,600	)		(4,490	)		(76,267	)
Impairment loss on investment		—			(700,000	)		(300,000	)		(700,000	)
Net loss	$	(1,191,966	)	$	(1,441,802	)	$	(3,240,994	)	$	(3,865,216	)
Deemed dividend on preferred stock		627,705			—			627,705			—
Net loss applicable to common stockholders	$	(1,819,671	)	$	(1,441,802	)	$	(3,868,699	)	$	(3,865,216	)
Net loss per share – Basic and diluted
Net loss per share – Basic and diluted	$	(0.14	)	$	(0.12	)	$	(0.30	)	$	(0.36	)
Weighted average common shares outstanding		12,902,549			12,261,971			12,818,232			10,730,928

See accompanying notes, which are an integral part of these condensed consolidated financial statements.

TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended September 30,
	2015			2014
Cash Flows From Operating Activities
Net loss	$	(3,240,994	)	$	(3,865,216	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		7,677			10,515
Provision for obsolete inventory		—			75,000
Stock-based compensation		961,218			508,444
Impairment loss on investments		300,000			700,000
Changes in operating assets and liabilities
Prepaid expenses and other assets		183,129			12,312
Other long-term assets		9,989			60,000
Accounts payable		416,982			77,465
Accrued liabilities		432,665			(11,654	)
Net cash used in operating activities		(929,334	)		(2,433,134	)
Cash Flows From Financing Activities
Cash advance from officer	130,818				652,289
Proceeds from subscribed shares issuable – common stock		600,000			—
Net proceeds from sales of preferred and common stock		—			1,829,999
Net cash provided by financing activities		730,818			2,482,288
Net increase (decrease) in cash		(198,516	)		49,154
Cash and cash equivalents at beginning of period		216,733			22,489
Cash and cash equivalents at end of period	$	18,217		$	71,643
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	4,490		$	—
Non-Cash Activity:
Warrants issued in settlement of accounts payable	$	—		$	3,200

See accompanying notes, which are an integral part of these condensed consolidated financial statements.

TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1—Organization and Liquidity

Organization

Taxus Cardium sp was incorporated in Delaware in December 2003. We are a holding company that operates a medical technologies portfolio of equity-based and potential royalty-driven investments as follows: (1) Angionetics, currently a majority-owned subsidiary focused on the late-stage clinical development and commercialization of Generx®, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease; (2) Activation Therapeutics a wholly owned subsidiary focused on the development and commercialization of the Excellagen® technology platform, the U.S. Food and Drug Administration (“FDA”)-cleared flowable dermal matrix for advanced wound care that has we believe broad potential applications as a delivery platform for small molecule drugs, proteins and biologics; (3) LifeAgain a wholly-owned subsidiary that has developed, an advanced medical data analytics (ADAPT®) technology platform focused on developing new and innovative products for the life insurance and healthcare sectors; and (4) a minority investment in Healthy Brands Collective, a functional food and nutraceutical company which acquired the Company’s To Go Brands® business.

Formation of Angionetics Inc.

Angionetics, a biotechnology company, incorporated by Taxus Cardium on April 13, 2015, was formed to create a separate company to develop Taxus Cardium’s Generx® cardiovascular gene therapy product candidate and technology platform. Our management team believes that the Generx® platform is undervalued in the current Taxus Cardium capital structure and believes that contributing the Generx® business to a separate entity will increase the opportunities for financing the continued development of Generx® through Phase III clinical trials. Taxus Cardium contributed to Angionetics all of the rights to our Generx® platform technology and will sell shares in Angionetics in order to raise capital based on a valuation of the Generx® platform technology for the purpose of funding the development and commercialization of Generx®. Our management also believes that funding for Generx® as a stand-alone company can be done at better pricing, resulting in less dilution and a “value unlock” for Taxus Cardium shareholders. The Company intends to retain a significant interest in Angionetics and return value to shareholders based on an increased value of its holdings through the independent external market valuation of Angionetics and the Generx® platform technology.

Following the formation of Angionetics, our management team initiated a comprehensive review of the global Generx® regulatory and clinical dossier, and elected to primarily focus on the clinical advancement and registration of Generx® in the United States and China, which we believe to be the most dynamic medical markets in the world for new and novel breakthrough products such as the Generx® product candidate. As a result of this review, Angionetics now plans to focus on the late stage clinical and commercial development of Generx® in key target markets that include the U.S. and China.

LifeAgain Activities

On August 11, 2015, Symetra Financial Corporation (“Symetra”), our financial partner for LifeAgain initial Blue Metric term life insurance program for men with prostate cancer, announced that it entered into a definitive merger agreement with Sumitomo Life Insurance Company (“Sumitomo Life”) pursuant to which Sumitomo Life will acquire all of the outstanding shares of Symetra. Following the transaction, Symetra advised the Company that it was discontinuing its partnership with LifeAgain. LifeAgain plans to continue to seek opportunities for the application of medical analytics to commercialize “survivable risk” term life insurance for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards as well as other forms of survivable risk programs. On April 4, 2015, Taxus Cardium entered into a license agreement with Shenzhen Qianhi Taxus Industry Capital Management Co., Ltd., a company affiliated with Shanxi Taxus Pharamaceuticals Co. Ltd., for the license of LifeAgain’s medical analytics technology to develop and commercialize survivable risk life insurance products in Greater China.

Liquidity and Going Concern

As of September 30, 2015, we had $18,217 in cash and cash equivalents. Our working capital deficit at September 30, 2015 was $3,370,406.

We anticipate that negative cash flow from operations will continue for the foreseeable future. We have yet to generate positive cash flows from operations, and are essentially dependent on equity and debt funding to finance our operations. We do not have any unused credit facilities. As long as any shares of the Company’s Series A Convertible Preferred Stock are outstanding, we have agreed

that we will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, or incur any liens other than specified “Permitted Liens”.

Our history of recurring losses, and uncertainties as to whether the Company’s operations will become profitable, raise substantial doubt about our ability to continue as a going concern.

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with the accounting principles generally accepted in the United States (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to continue its operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. The condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the condensed consolidated financial statements.

We intend to secure additional working capital through sales of equity securities and debt to finance our operations, or the sale of certain equity interests in the Company businesses, technology platforms, products or product candidates and licensing agreements covering the marketing and sale of Excellagen and Generx in certain geographic markets and regions.

On April 4, 2015, we entered into a binding term sheet with Shenzhen Qianhai Taxus Industry Capital Management Co., Ltd. (“Shenzhen Qianhai Taxus”), as a lead investor, to purchase an equity stake in Angionetics. Under the terms of the agreement, Shenzhen Qianhai Taxus agreed to acquire 15% of Angionetics’ outstanding common stock for an aggregate purchase price of $3,000,000, payable in three tranches with the final payment due by May 31, 2015. Shenzhen Qianhai Taxus paid $600,000, but did not complete the transaction. See (Note 7)—Subsequent Events below. The $600,000 investment has been recorded as Subscribed shares issuable – common stock.

Note 2—Summary of Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements contained in this report have been prepared in accordance with GAAP for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of our management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2015 and the results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future period.

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Our accounting policies are described in the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and updated, as necessary, in this Quarterly Report on Form 10-Q.

Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates impacting the financial statements contained in this report include reserve for inventory, which is currently reserved at 100%, valuing options and warrants using option pricing models.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivable, advances from related party, accounts payable, and accrued liabilities approximate fair value due to the short term maturities of these instruments.

Principles of Consolidation

The consolidated financial statements include the accounts of Taxus Cardium Pharmaceuticals Group, Inc. and its consolidated subsidiaries, Angionetics Inc., Activation Therapeutics, Inc. and LifeAgain Insurance Solutions, Inc. All significant inter-company transactions and balances have been eliminated in consolidation.

Preferred Stock

We apply the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of our preferred stock. Shares that are subject to mandatory redemption, if any, are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.

Research and Development

In accordance with Accounting Standard Codification (“ASC”) Topic 730 “Research and Development”, research and development costs are expensed as incurred. Research and development expenses consist of purchased technology, purchased research and development rights and outside services for research and development activities associated with product development. In accordance with ASC Topic 730, the cost to purchase such technology and research and development rights are required to be charged to expense if there is currently no alternative future use for this technology and, therefore, no separate economic value.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not to be sustained upon examination.

The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Common Stock Purchase Warrants

We account for common stock purchase warrants issued in connection with capital financing transactions in accordance with the provisions of ASC Topic 815 “Derivatives and Hedging”. Based upon the provisions of ASC Topic 815, we classify as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

Earnings (Loss) Per Common Share

We compute earnings (loss) per share, in accordance with ASC Topic 260 “Earnings per Share”, which requires dual presentation of basic and diluted earnings per share. Basic earnings (loss) per common share is computed by dividing earnings (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing earnings (loss) by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. As of September 30, 2015, potentially dilutive securities consist of preferred stock convertible into 3,718,804 shares of common stock and outstanding stock options and warrants to acquire 7,353,848 shares of common stock. As of September 30, 2014, potentially dilutive securities consisted of preferred stock convertible into 1,826,380 shares of common stock and outstanding stock options and warrants to acquire 2,434,936 shares of

our common stock. These potentially dilutive securities were not included in the calculation of loss per common share for the nine months ended September 30, 2015 or 2014 because their effect would be anti-dilutive.

Stock-Based Compensation

Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.

Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:

	For the Three Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	—
General and administrative		670,833		1,161
Total stock-based compensation	$	703,384	$	1,161

	For the Nine Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	51,409
General and administrative		928,667		457,035
Total stock-based compensation	$	961,218	$	508,444

Investments

We periodically reviews the carrying amount of our investments to determine whether the value is impaired or a write down may be necessary for other than temporary decline in value. During the nine months ended September 30, 2015, we recorded $300,000 in impairment expense related to our investment in Cell-nique (the owner of Healthy Brands Collective) as our management does not anticipate future cash flows from the investment.

Recent Accounting Pronouncements

In March, 2016, the Financial Accounting Standards Board (“FASB”) issued (“ASU”) ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This standard is intended to improve the accounting for employee share-based payments and affects all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted. We do not believe the adoption of this standard will have a material effect on our consolidated financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. We are currently evaluating this ASU to determine its impact on our consolidated net income, financial position, cash flows and disclosures.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. We are currently evaluating ASU 2015-17 to determine if this guidance will have a material impact on our financial position, results of operations or cash flows.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. ASU 2015-11 applies only to inventories for which cost is determined by methods other than last-in first-out and the retail inventory method. ASU 2015-11 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption of ASU 2015-11 is permitted. We are currently evaluating ASU 2015-11 to determine if this guidance will have a material impact on our financial position, results of operations or cash flows.

In August 2014, the FASB issued Accounting Standards Update ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU is intended to provide guidance on the responsibility of reporting entity management. Specifically, this ASU provides guidance to management related to evaluating whether there is substantial doubt about the reporting entity’s ability to continue as a going concern and about related financial statement note disclosures. The FASB issued this guidance to require management evaluation and potential financial statement disclosures. ASU 2014-15 is effective for financial statements with periods ending after December 15, 2016. We are currently evaluating ASU 2014-15 to determine its impact on our financial position, results of operations or cash flows.

Note 3—Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2015 (unaudited)		December 31, 2014
Payroll and benefits	$	634,677	$	465,512
Technology fees		187,500		—
Other		145,739		69,739
Total	$	967,916	$	535,251

Note 4—Advances From Related Party - Officer

Officers of the Company occasionally incur or advance expenses on behalf of the Company, which are subsequently reimbursed to the officers along with any associated costs. As of September 30, 2015 and December 31, 2014, $819,251 and $688,433, respectively, in net Company expenses incurred in the ordinary course of business that have been paid by or with cash advanced by the Company’s Chief Executive Officer.

Note 5—Stockholders’ Equity

Preferred Stock

Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd.

On April 4, 2013, we entered into a securities purchase agreement with Sabby Healthcare Volatility Master Fund, Ltd. (“Sabby”) to purchase up to 4,012 shares of our newly authorized Series A Convertible Preferred Stock (the “Preferred Stock”) for maximum proceeds of $4.0 million. The Preferred Stock was convertible into shares of our common stock at an initial conversion price of $0.6437 per share. In addition, the conversion price is subject to downward adjustment if we issue common stock or common stock equivalents at a price less than the then effective conversion price. Sabby is limited to hold no more than 10% of Taxus Cardium’s issued and outstanding common stock at any time. As long as the Preferred Stock is outstanding, we have also agreed not to incur specified indebtedness without the consent of the holders of the Preferred Stock. These factors may restrict our ability to raise capital through equity or debt offerings in the future.

On July 22, 2015, we entered into an Exchange and Redemption Agreement with Sabby relating to the 1,176 outstanding shares of Preferred Stock that remained outstanding at that time. Under the terms of the Exchange and Redemption Agreement, we agreed to reduce the conversion price sp of the Preferred Stock to sp $0.30 per share. The Agreement grants Taxus Cardium (1) a right to redeem any or all of the outstanding Preferred Stock for its stated value (approximately $1,000 per share) at any time during a 120 day period after the date of the Agreement, and (2) increases the limitation on certain indebtedness contained in the Certificate of Designation for the Preferred Stock to allow Taxus Cardium to borrow up to $250,000. We entered into the Agreement to increase our options for retiring the outstanding Preferred Stock and financing our continued business operations. As a result of the effective conversion price changing from $0.64 to $0.30 per share, the 1,176 shares of Preferred Stock outstanding are convertible to 3,918,667 shares of Taxus Cardium common stock, an additional 2,092,350 compared to before the conversion price change. A hypothetical conversion of all of the outstanding Preferred Stock into 3,718,667 common shares would increase the common stock outstanding

from 12,975,044 shares as of September 30, 2015, to 16,693,711, an increase of 29%. As a result of such holder entering into this modification agreement, the holder received additional incremental shares, with a fair market value at the date of modification, totaling $627,705. This additional value was reflected as a deemed dividend in the statement of operations in arriving at net loss to common shareholders..

This reduction of the conversion price under the Exchange and Redemption Agreement triggered an anti-dilution protection in 3,485,908 previously granted common stock purchase warrants not held by Sabby, resulting in an additional 3,749,692 warrant shares to be granted for a total of 7,235,600 common stock purchase warrants with anti-dilutive provisions outstanding. The exercise price per common share in these warrants remains unchanged as the original common stock purchase warrant, a weighted average price of $0.71. Stock-based compensation expense of $693,801 related to this anti-dilution provision was recorded during the three months ended September 30, 2015.

Stock Options and Other Equity Compensation Plans

We have an equity incentive plan that was established in 2005 under which 283,058 shares of the Company’s common stock have been reserved for issuance to employees, non-employee directors and consultants of the Company.

At September 30, 2015, the following shares were outstanding and available for future issuance under the option plan:

Plan

Outstanding

Available

for Issuance

2005 Equity Incentive Plan

78,250

204,808

On February 28, 2014, outside of the 2005 Equity Incentive Plan, we issued 1,457,100 common stock warrants to directors, officers and chief medical advisor. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.80 per share, which represented a 57% premium to the closing stock price on the date of issuance. The common stock warrants had a fair value of $0.34 per share and vested immediately.

On March 23, 2015, outside of the 2005 Equity Incentive Plan, we issued 1,125,000 common stock warrants to directors, officers and chief medical advisor. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 216% premium to the closing stock price on the date of issuance. The warrants had a fair value of $0.10 per share and vested immediately.

On March 23, 2015, we issued 10,000 non-qualified stock options to directors. The options were approved by our Board of Directors, have a seven year term and an exercise price of $0.19 per share, which equaled the closing stock price on the date of issuance. The stock options had a fair value of $0.14 per share.

On May 1, 2015, outside of the 2005 Equity Incentive Plan, we issued 550,000 common stock warrants to directors and employees. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 20% premium to the closing stock price on the date of issuance. The warrants had a fair value of $0.37 per share and 300,000 vested immediately. 250,000 warrants have a 1 year cliff vesting.

On May 8, 2015, outside of the 2005 Equity Incentive Plan, we issued 100,000 common stock warrants to a consultant. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 33% premium to the closing stock price on the date of issuance. The commons stock warrants had a fair value of $0.41 per share. 40,000 warrants vested immediately, and the remaining 60,000 warrants vested over three quarters. On August 4, 2015, the consulting agreement was terminated and the remaining 60,000 unvested warrants cancelled per the terms of the consulting agreement and the common stock purchase warrant.

The following is a summary of stock option and warrant activity under the 2005 Equity Incentive Plan as well as the warrants issued outside of the plan to employees and consultants, during the nine months ended September 30, 2015:

	Number of Options or Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance outstanding, December 31, 2014		1,914,906		$	2.44		8.74
Granted		5,534,692		0.67			9.10
Cancelled (unvested)		(60,000	)	0.60			—
Expired (vested)		(35,750	)	$	24.11		—
Balance outstanding, September 30, 2015		7,353,848		$	1.02		8.85
Balance exercisable, September 30, 2015		7,093,841		$	1.04		8.83

As of September 30, 2015, the Company had $50,732 of unvested stock-based compensation at fair value remaining to be expensed.

As of September 30, 2015, there was no intrinsic value to the outstanding and exercisable options and warrants as their exercise price exceeded the market price of our common stock.

The 2005 Equity Incentive Plan expired on October 20, 2015, ten years after its adoption, and we are no longer able to issue share or awards under that plan. All options or other awards issued under the 2005 Equity Incentive plan prior to its expiration remain outstanding in accordance with their terms.

Warrants

In addition to the warrants that we have issued as a form of compensation above, we have issued wattants to investors in connection with certain financing transactions. The following table summarizes outstanding warrants as of September 30, 2015:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance outstanding, December 31, 2014		873,336		$	17.79		1.06
Warrants expired		(156,586	)		26.07
Balance outstanding, September 30, 2015		716,750		$	15.98		0.47
Warrants exercisable at September 30, 2015		716,750		$	15.98		0.47

As of September 30, 2015, there was no intrinsic value to the outstanding and exercisable warrants as their exercise price exceeded the market value of our common stock.

Note 6—Commitments and Contingencies

In the course of our business, we are routinely involved in proceedings such as disputes involving goods or services provided by various third parties, which we do not consider likely to be material to the technology we develop or license, or the products we develop for commercialization, but which can result in costs and diversions of resources to pursue and resolve. In October 2014, we received a complaint filed by BioRASI LLC (“BioRASI”) in Broward County, Florida, seeking payments of approximately $0.5 million allegedly owed for services that BioRASI provided in connection with the Company’s clinical trial conducted in the Russian Federation. We are defending the action and have filed counterclaims. Although at September 30, 2015, the probable outcome of this matter cannot be determined, we believe that we have supportable defenses and any negative decision, if any, is expected to be insignificant. Accordingly, we have not recorded any provisions related to this matter.

Note 7—Subsequent Events

We have evaluated events that occurred subsequent to September 30, 2015 and through the date the condensed consolidated financial statements were issued.

Angionetics Formation

On June 6, 2016, Taxus Cardium entered into a contribution agreement with Angionetics, pursuant to which Taxus Cardium contributed all of the assets and certain related liabilities related to the Generx^® product candidate to Angionetics. In consideration of the contribution, Angionetics agreed to pay to Taxus Cardium a $2,000,000 technology fee, payable upon the earlier of a qualified initial public offering of Angionetics capital stock or a change in control of Angionetics. The contribution agreement also provides certain restrictions and registration rights related to Taxus Cardium’s holding in Angionetics capital stock. Taxus Cardium agreed to a twelve-month lock up on its shares of Angionetics following any qualified initial public offering of Angionetics common stock. Angionetics also granted Taxus Cardium piggyback registration rights, subject to certain cutbacks, for so long as Taxus Cardium continues to hold more than 9.99% of Angionetics’ outstanding capital stock. The contribution agreement contains mutual covenants regarding the protection of confidential non-public information shared between each entity. Finally, the contribution agreement provides for cross-indemnification where Taxus Cardium will indemnify Angionetics for any claims arising out of the operation of its business (excluding Generx and its related assets and liabilities), and Angionetics will indemnify Taxus Cardium for any claims arising out of the operation of its business.

On June 6, 2016, Taxus Cardium entered into a services agreement with Angionetics, pursuant to which Taxus Cardium agreed to provide services to Angionetics during a transition period. The services agreement provides that Taxus Cardium will assist Angionetics with the transfer of the Generx assets and liabilities without charge. Taxus Cardium has also agreed to provide certain administrative, commercial and clinical development services to Angionetics on a cost basis. Angionetics has also been granted a license to use certain of Taxus Cardium’s facilities in exchange for payment of 70% of the costs of the facilities. The transition services are provided without warranty or liability except in the case of fraud or willful misconduct. The services agreement also contemplates that as Angionetics develops its financing and business plan, it is anticipated that certain Taxus Cardium employees critical to the development of the Generx^® product candidate will become employees of Angionetics.

Schering AG Technology Transfer Agreement

We are party to a Technology Transfer Agreement between Schering AG (now Bayer Pharma AG), Berlex, Inc. (now Bayer Healthcare Pharmaceuticals Inc), Collateral Therapeutics, Inc., and Taxus Cardium which covers the transfer or license of certain assets and technology, including patents relating to (i) methods of gene therapy for the treatment of cardiovascular disease (including methods for the delivery of genes to the heart or vasculature and the use of angiogenic and/or non-angiogenic genes for the potential treatment of diseases of the heart or vasculature); (ii) therapeutic genes that include fibroblast growth factors (including FGF-4); insulin-like growth factors (including IGF-I); and potentially other related biologics; and (3) other technology and know-how, including manufacturing and formulation technology, as well as data relating to the clinical development of Generx and corresponding FDA regulatory matters. Under this agreement, we paid Schering AG a $4.0 million upfront fee and, as the current holder of the license rights, are obligated to make a $10 million milestone payment upon the first commercial sale of each product using the licensed technology.

On May 4, 2016, Bayer Pharma AG agreed to the transfer of the Technology Transfer Agreement from Taxus Cardium to Angionetics. Accordingly, Angionetics has assumed the obligation for any milestone payment required to be paid to Bayer Pharma AG. Under the terms of the Technology Transfer Agreement, Angionetics also may be obligated to pay the following royalties to Bayer Pharma AG: (i) 5% on net sales following a first commercial sale of an FGF-4 based product in the United States, Europe, or Japan, or (ii) 4% on net sales of other products developed based on technology transferred by Bayer Pharma AG (as successor to Schering AG) following a first commercial sale in the United States, Europe, or Japan, and (iii) a royalty of 2.5% (for FGF-4 based technology) or 2% (for other products) in territories where the product would not infringe the patents licensed by Bayer Pharma AG (as successor to Schering AG). Angionetics will also be obligated to reimburse Bayer Pharma AGfor patent expenses, including the expenses of any interference or other proceedings, accrued on or after April 1, 2005 in connection with the transferred technologies. To date there have been no sales or payments under this agreement.

Huapont Life Sciences Angionetics Financing Agreement

effective agricultural herbicides (including NC16, NC34, NC36, NC125, NC201) serving the agricultural business throughout the U.S. and South American markets. Huapont’s pharmaceutical business includes dermatology products, cardiovascular products, anti-tuberculosis agents, autoimmune-related products and oncology-related products. Huapont’s API business involves the production and sale of bulk pharmaceutical chemicals, pharmaceutical intermediates and preparations of Western medicines, with current annual revenues of approximately $1.1 billion, and approximately 7,100 employees operating throughout mainland China. Huapont is listed on the Shenzhen Stock Exchange (002004.SZ) and trades at a current market capitalization of approximately $3.0 billion.

Pursuant to the Share Purchase Agreement, Angionetics agreed to sell 600,000, shares of its newly authorized Series A Convertible Preferred Stock (the “Shares”) to the Huapont affiliate in exchange for $3,000,000 in cash. The Shares represent an initial 15% equity interest in Angionetics, resulting in a post-money valuation of $20.0 million for Angionetics, subject to certain anti-dilution protection described below.

The investment from the Huapont affiliate was to be made in two tranches. The closing of the initial tranche of 200,000 Shares for $1,000,000 occurred on July 5, 2016. The closing of the second tranche of 400,000 Shares for $2,000,000 was conditioned upon Angionetics securing FDA clearance to initiate a new U.S.-based Phase 3 clinical study (the AFFIRM study) to evaluate the safety and definitive efficacy of the Generx® [Ad5FGF-4] product candidate for the treatment of patients with ischemic heart disease and refractory angina. On September 28, 2016, following FDA clearance of the Phase 3 AFFIRM study, Angionetics received $2,000,000 from the closing of the second tranche. Angionetics will require additional capital to complete the Phase 3 AFFIRM study, which it expects to secure through the sale of additional equity or debt securities. There are no agreements or arrangement for any additional financing in place at this time.

The Angionetics Shares have the following rights, privileges and preferences:

•

Dividends. Holders of the Shares are entitled to receive dividends as, when and if declared by the Angionetics board of directors on the Angionetics common stock, on an as-converted basis.

•

Liquidation. In the event of a liquidation of Angionetics, including a change of control transaction, holders of sp the Shares are entitled to be paid an amount equal to their investment amount before any payment is made to Taxus Cardium or any other holders of Angionetics common stock.

•

Voting. The Shares generally vote with the Angionetics common stock as a single class on an as-converted basis. Holders of the Shares also have certain special voting rights as a separate class including (a) the right to appoint a member to the Angionetics board of directors, (b) the right to approve any increase or decrease in the number of authorized shares of the Shares or the common stock, any merger or acquisition involving Angionetics, any liquidation or winding up of Angionetics, any increase in the number of directors and any dividend or distribution, and (c) the right to approve any amendment to the Angionetics certificate of incorporation in a manner that adversely affects the rights of the Shares. The voting rights under (a) and (b) terminate if Huapont does not complete the second closing under the share purchase agreement.

•

Conversion. The Shares are convertible into shares of Angionetics common stock at any time at the holder’s election. The Shares automatically convert into common stock upon the closing of a firm commitment underwritten public offering of Angionetics common stock. The Shares are initially convertible on a one to one basis into Angionetics common stock. The Shares are subject to anti-dilution protection, such that in the event of a firm commitment underwritten public offering or a change in control each Share will be convertible into a pro rata portion of 15% of the outstanding Angionetics common stock at the time of the public offering or change in control.

The Huapont financing replaced the prior April 4, 2015 term sheet with Shenzhen Qianhai Taxus, whereby Taxus Cardium proposed to sell Shenzhen Qianhai Taxus 600,000 shares of Angionetics common stock in exchange for $3.0 million in cash. The $3.0 million was to be paid in tranches that were to be completed by May 31, 2015. Shenzhen Qianhai Taxus paid $600,000 of the purchase price, but did not complete the investment. The $600,000 payment has been recorded as Subscribed shares issuable – common stock. This contribution is committed and not refundable to Shenzhen Qianhai Taxus.

Generx License Agreement in Mainland China

On June 7, 2016, Angionetics entered into a Distribution and License Agreement with an entity affiliated with Huapont. Under the terms of the agreement the Huapont affiliated entity has been granted an exclusive license to clinically develop, manufacture, market and sell the Generx® [Ad5FGF-4] angiogenic gene therapy product candidate in mainland China.

make regulatory filings and take such other actions as may be necessary to commercialize Generx® in mainland China. Huapont’s affiliated entity will assume the costs associated with the commercial development of Generx® in mainland China.

The Distribution and License Agreement provides for the Huapont affiliate to make quarterly royalty payments to Angionetics at a rate of 10% of net sales of Generx® products in mainland China, reducing to a 5% royalty based on the volume of annual sales. The royalty payments commence on the first commercial sale and expire on the earlier of the termination of any patent or regulatory exclusivity in China or fifteen years after the first commercial sale. The term of the agreement continues (unless terminated for breach) until Huapont’s affiliate has no remaining payment obligations to Angionetics. Upon expiration (but not an earlier termination) Huapont’s affiliate shall have a perpetual, non-exclusive, fully paid-up, and royalty free license to Generx® in mainland China.

FDA Approval of Phase 3 Clinical Trial for Generx

On December 18, 2015, pursuant to Section 505(i) of the U.S. Federal Food, Drug and Cosmetic Act, Angionetics submitted a request to the FDA Center for Biologics Evaluation and Research requesting transfer of sponsorship for the Generx Investigational New Drug (IND) application to Angionetics. Transfer of sponsorship was acknowledged by the FDA on January 5, 2016. Additionally, the FDA acknowledged Angionetics’ U.S. activation of the Ad5FGF-4 (Generx) Investigational New Drug Application (IND) pursuant to Section 505(i) of the Federal Food, Drug and Cosmetic Act. Consequently, the previously granted FDA “Fast Track” designation for the Generx development program continues forward. In addition, Angionetics submitted for FDA clearance a new U.S.-based Phase 3 clinical study protocol (the “AFFIRM” study) to evaluate the further safety and definitive efficacy of Generx [Ad5FGF-4] for men and women with advanced ischemic heart disease and refractory angina.

On September 9, 2016, the U.S. FDA Center for Biologics Evaluation and Research (CBER) cleared Angionetics’ AFFIRM Phase 3 clinical study protocol, thus allowing Angionetics to proceed with late-stage clinical evaluation of Generx. The AFFIRM study patient population and trial design are based on Ad5FGF-4 responder data from the four prior FDA-cleared clinical studies. The primary efficacy endpoint is improvement in exercise treadmill test (ETT) duration in Generx-treated patients compared to a placebo control group. Enrolled patients must have refractory angina, documented clinical evidence of myocardial ischemia, clinically significant limitation of physical activity due to angina, and angina-limited ETT duration of 3-7 minutes.

Status of Term Sheet with Dr. Reddy’s and Russian Generx Clinical Development Program

Following the formation of Angionetics, our management team initiated a comprehensive review of Taxus Cardium’s global Generx regulatory and clinical dossier, and elected to primarily focus on the clinical advancement and registration of Generx in the United States and China, which we believe to be the most dynamic medical markets in the world for new and novel breakthrough products such as the Generx product candidate. As a result of this review, on July 13, 2016 the Company notified Dr. Reddy’s of its plan to discontinue its planned Generx development in the Russian Federation and other countries set forth in the term sheet and now plans to focus on the late stage clinical and commercial development of Generx in key target markets that include the U.S. and China. Consequently, the commercialization opportunity with Dr. Reddy’s Laboratories, previously reported by Taxus Cardium, will not be advanced to a definitive agreement.

Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd.

On September 23, 2016, we entered into a second Exchange and Redemption Agreement with Sabby covering the 1,000 shares of Preferred Stock outstanding at the time. Under the terms of the Exchange and Redemption Agreement, Taxus Cardium agreed to reduce the conversion price at which Sabby can convert shares of Preferred Stock to common shares to an effective price of $0.18 per share. The Exchange and Redemption Agreement grants Taxus Cardium a right to redeem any or all of the outstanding Preferred Stock for its Stated Value (approximately $1,000 per share) at any time after the date of the Agreement until November 29, 2016. We entered into the Agreement to increase our options for retiring the outstanding Preferred Stock and financing our continued business operations. As a result of the conversion price changing from $0.30 to $0.18 per share, the 1,000 shares of Preferred Stock outstanding are convertible to 5,554,667 shares of Taxus Cardium common stock, an additional 2,221,867 compared to before the conversion price change. A hypothetical conversion of all of the outstanding Preferred Stock of 946 shares as of October 27, 2016 into 5,254,444 common shares would increase the common stock outstanding from 13,623,544 shares as of October 27, 2016, to 18,877,988, an increase of 39%.The reduction in the conversion price under the Exchange and Redemption Agreement triggered an anti-dilution protection in 7,235,600 previously granted common stock purchase warrants not held by Sabby, resulting in an additional 4,823,733 warrant shares to be granted for a total of 12,059,333 common stock purchase warrant with anti-dilutive provisions outstanding. The exercise price per common share in these warrants remains unchanged as the original common stock purchase warrant, a weighted average price of $0.71.

Outstanding Capital Stock, Stock Options, and Warrants

As of October 27, 2016, there were 13,623,544 shares of common stock issued and outstanding. There were 945.80 issued and outstanding shares of Series A Convertible Preferred Shares which are now convertible into 5,254,444 shares of common stock. In addition, there are 78,250 shares of common stock issuable upon the exercise of stock options which were awarded under the 2005 Equity Incentive Plan, which have a weighted average exercise price of $30.25 per share. As of October 27, 2016, there are 12,099,333 shares of common stock issuable upon the exercise of outstanding warrants which have an average exercise price of $0.71 per share for a total conversion price of $8,554,800, these warrants may also be redeemed through a cashless exercise whereby the warrant holder surrenders the required number of warrants needed to exercise the remaining warrants.

Office Lease

On June 23, 2016, we entered into a thirty-eight month lease agreement to lease office space commencing on September 30, 2016. The approximate base monthly rent in the first, second and third years is $3,500, $3,700, and $3,800 respectively. The base monthly rent in the final two months of the agreement is $3,900. The total base rent over the lease term equals $139,800.

Related Party Transactions

Officers of the Company occasionally incur or advance expenses on behalf of the Company, which are subsequently reimbursed to the officers along with any associated costs. As of September 30, 2016, $1,063,865 in net Company expenses incurred in the ordinary course of business have been paid by or with cash advanced by the Company’s Chief Executive Officer. This amount that has been advanced by the Chief Executive Officer is non-interest bearing.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis is intended to help you understand our financial condition and results of operations for the three month and the nine month periods ended September 30, 2015. You should read the following discussion and analysis together with our unaudited condensed consolidated financial statements and the notes to the condensed consolidated financial statements included under Item 1 in this report, as well as the risk factors and other information included in Part II, Item 1A, in our annual report on Form 10-K for our year ended December 31, 2014 (our “2014 Annual Report”), and other reports and documents we file with the United States Securities and Exchange Commission (“SEC”). Our future financial condition and results of operations will vary from our historical financial condition and results of operations described below.

Overview

The following overview does not address all of the matters covered in the other sections of this Item 2 or other items in this report or contain all of the information that may be important to our stockholders or the investing public. This overview should be read in conjunction with the other sections of this Item 2 and this report.

Taxus Cardium was incorporated in Delaware in December 2003. We are a holding company that operates a medical technologies portfolio of equity-based and potential royalty-driven investments as follows: (1) Angionetics, currently a majority-owned subsidiary focused on the late-stage clinical development and commercialization of Generx®, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease; (2) Activation Therapeutics, Inc. a wholly owned subsidiary focused on the development and commercialization of the Excellagen® technology platform, an FDA-cleared flowable dermal matrix for advanced wound care that we believe has broad potential applications as a delivery platform for small molecule drugs, proteins and biologics; (3) LifeAgain a wholly-owned subsidiary that has developed, an advanced medical data analytics (ADAPT®) technology platform focused on developing new and innovative products for the life insurance and healthcare sectors; and (4) a minority investment in Healthy Brands Collective, a functional food and nutraceutical company which acquired the Company’s To Go Brands® business.

Our history of recurring losses, and uncertainties as to whether our operations will become profitable, raise substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. We have yet to generate positive cash flows from operations, and are essentially dependent on debt and equity funding to finance our operations.

Business Strategy

We are currently focused on achieving key milestones with the potential to offer significant valuation inflection points of our core medical technology assets, while evaluating options for sales or other monetizations of our non-core investments. The key elements of our current business strategy include:

•

Support Angionetics in the development and commercialization of Generx, an angiogenic, gene-based bio-therapeutic for the treatment of almost 1.0 million patients in the U.S. who have late-stage coronary artery disease and refractory angina and other ischemic heart disorders and medical conditions, including support in the funding and operation of the AFFIRM U.S.-based Phase 3 clinical trial.

•

Strategically partner and monetize or sell Activation Therapeutics’ FDA-cleared pharmaceutically formulated collagen commercial wound care product Excellagen, for selected U.S.-based vertical market channels and leverage Excellagen’s advanced regenerative medicine delivery platform by identifying innovative product extensions for tissue regeneration based on stem cells (including exosomes), biologics, peptides and/or small molecule drugs for future development and commercialization with one or more strategic partners;

•

Monetize our equity stake in Healthy Brands Collective investment. We acquired this investment through the sale of our To Go Brands health sciences business through an asset exchange for a preferred equity position in Healthy Brands Collective;

•

Identify a new insurance partner and seek opportunities for the application LifeAgain’s Medical analytics to commercialize “Survivable risk” term life insurance for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional under writing standards as well as other forms of survivable risk programs.

•

With the successful monetization of current business interests we plan to redeploy capital strategically to acquire and develop new and innovative medicine product candidates and create shareholder value.

Recent highlights of our operating activities include the following:

Angionetics Inc. & Generx [Ad5FGF-4] Product Candidate

Angionetics, a biotechnology company, incorporated by Taxus Cardium on April 13, 2015, was formed to create a separate company to develop Taxus Cardium’s Generx® cardiovascular gene therapy technology platform. Our management team believes that the Generx® platform is undervalued in the current Taxus Cardium capital structure and believes that contributing the Generx® business to a separate entity will increase the opportunities for financing the continued development of Generx® through Phase III clinical trials. Our management also believes that funding for Generx as a stand-alone company can be done at better pricing, resulting in less dilution and a “value unlock” for Taxus Cardum shareholders. Taxus Cardium contributed to Angionetics all of the rights to our Generx platform technology and will sell shares in Angionetics in order to raise capital based on a valuation of the Generx platform technology for the purpose of funding the development and commercialization of Generx. The Company intends to retain a significant minority interest in Angionetics and return value to shareholders based on an increased value of its holdings through the independent external market valuation of Angionetics and the Generx platform technology.

Generx [Ad5FGF-4] is a disease-modifying, precision medicine, angiogenic gene therapy for patients with refractory angina and inducible ischemia on stress testing, that is designed to improve myocardial perfusion and exercise tolerance by promoting the formation of functional coronary collateral vessels. This process, referred to as “medical revascularization”, represents a fundamentally new mechanism of action that involves stimulation of the formation of new biological structures in the heart, through arteriogenesis (enlargement of existing arterioles) and angiogenesis (formation of new capillary vessels), as opposed to mechanical revascularization procedures (coronary artery bypass surgery and percutaneous coronary intervention) or the transient symptomatic relief of angina achieved with pharmacologic therapies.

Generx addresses an unmet medical need for patients with refractory angina who are no longer responsive to maximally tolerated medical therapy, and are not candidates for, and would receive no prophylactic therapeutic benefit from, percutaneous coronary intervention or coronary artery bypass surgery. Refractory angina patients with stress-induced ischemia are considered most likely to benefit from Ad5FGF-4 angiogenic therapy.

Ad5FGF-4 consists of human adenovirus serotype5 (Ad5) that has been modified to express the human fibroblast growth factor-4 (FGF-4) gene driven by a cytomegalovirus (CMV) promoter. The E1 region of the wild-type adenovirus vector has been deleted and replaced with the expression cassette for FGF-4. The E1-deleted adenovirus vector containing the FGF-4 gene expression cassette is replication deficient. Ad5FGF-4 is delivered to the heart using a standard cardiac balloon catheter. FGF-4 has been shown to be a key regulatory protein that is believed to promote both arteriogenesis and angiogenesis in ischemic regions of the heart.

Generx has been evaluated in five FDA-cleared clinical studies under an initial IND which was filed with the FDA, all for the medical indication of refractory angina. These studies have enrolled 672 patients, 455 of whom received a one-time intracoronary administration of Ad5FGF-4, which has consistently been found to be safe and well-tolerated (based on over 2,500 patient years of safety data). These studies were conducted at approximately 100 medical centers, primarily in the United States and Western Europe.

On January 5, 2016, after the period covered by this report, the FDA Center for Biologics Evaluation and Research has accepted and designated Angionetics Inc. as the sponsor, and acknowledged Angionetics’ U.S. activation of the Ad5FGF-4 (Generx) Investigational New Drug Application (IND) pursuant to Section 505(i) of the Federal Food, Drug and Cosmetic Act. The previously granted FDA “Fast Track” designation for the Generx development program continues forward. In addition, Angionetics submitted, for FDA clearance, a new U.S.-based Phase 3 clinical study protocol (the “AFFIRM” study) to evaluate the further safety and definitive efficacy of Generx [Ad5FGF-4] for men and women with advanced ischemic heart disease and refractory angina.

Angionetics has submitted the planned Generx [Ad5FGF-4] Phase 3 AFFIRM clinical study protocol to the FDA as well as updates to all key elements of the Generx IND. The submission included an updated Investigator’s Brochure and a summary of clinical efficacy and safety data from the four FDA cleared, U.S. and international clinical studies. The clinical data, including patient subset analyses, were used as the basis for the AFFIRM study design and target patient population. The updated long-term safety data totaled over 2,500 patient years, and represented the completed safety dataset for the prior clinical studies. A detailed review of product manufacturing procedures, testing strategies and up-to-date stability data were also provided to the FDA.

The new U.S.-focused AFFIRM clinical study protocol, as submitted to the FDA, incorporates important research innovations that include: (1) enhanced cardiac delivery procedures utilizing standard balloon catheters, supported by research showing that transient ischemia may enhance gene transfer to heart cells; and (2) a more comprehensively characterized target patient population

based on Ad5FGF-4 responder data from the four FDA cleared clinical studies. The study patient population includes patients with refractory angina (no longer responsive to anti-anginal medications and not a candidate for CABG or PCI), and documented clinical evidence of myocardial ischemia within the past 6 months. Patients must have clinically significant limitation of physical activity due to angina (CCS Class 3 or 4) and angina-limited baseline exercise treadmill test (ETT) duration of 3-7 minutes. The proposed primary efficacy endpoint will be improvement in ETT duration in Generx®-treated patients compared to a placebo control group. Secondary efficacy endpoints include change in CCS angina class, change in weekly angina frequency and nitroglycerin usage, and change in quality of life, assessed using the Seattle Angina Questionnaire (SAQ).

On September 9, 2016, after the period covered by this report, the U.S. FDA Center for Biologics Evaluation and Research (CBER) cleared Angionetics’ AFFIRM Phase 3 clinical study protocol, thus allowing Angionetics to proceed with late-stage clinical evaluation of Generx. The AFFIRM study patient population and trial design are based on Ad5FGF-4 responder data from the four prior FDA-cleared clinical studies. The primary objective of the AFFIRM study is to evaluate the effect of a one-time intracoronary infusion of Ad5FGF-4 on the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration using the Modified Bruce Protocol, with exercise duration limited by angina “grade 3” (patient feels chest pain that has increased to the point that he/she would stop activity and take nitroglycerin). The patient population consists of individuals with refractory angina (CCS Class III or IV), inducible ischemia on stress testing, who are no longer responsive to maximally tolerated medical therapy for angina, who are not candidates for standard interventions (coronary artery bypass surgery and percutaneous coronary intervention), and who have baseline ETT duration of 3-7 minutes. The primary efficacy endpoint is improvement in exercise treadmill test (ETT) duration in Generx-treated patients compared to a placebo control group.

Activation Therapeutics Inc. & Excellagen Dermal Matrix FDA-Cleared Product

Activation Therapeutics Inc., is a wholly-owned subsidiary established to hold and manage the Company’s assets related to the Excellagen® product and technology platform. We are seeking to monetize Excellagen through the sale of the technology and business unit or obtain strategic partners to support our future internal clinical and commercial development of Excellagen and the Excellagen Technology platform.

Excellagen® Dermal Wound Matrix: Excellagen is an FDA-cleared, pharmaceutically-formulated acellular biological modulator that has been engineered to activate and promote wound healing through the growth of granulation tissue in chronic non-healing diabetic foot, pressure and venous ulcers, as well as other dermal wounds (including traumatic and surgical wounds). We believe that Excellagen is a cost-effective, easy to use professional product that has now been classified for reimbursement purposes by the U.S. Centers for Medicare and Medicaid Services as a unique “skin substitute”- a designation which is consistent with other forms of skin substitutes including living skin equivalents Dermagraft ^® and Apligraf ^® and human dermal and amnion placental tissue-based products including Graftjacket ^® and EpiFix ^®.

Excellagen is a flowable homogenate of pharmaceutically formulated, highly purified bovine dermal collagen (Type I) in its native 3-dimensional fibrillar configuration. Excellagen^® dermal wound matrix was cleared by FDA via the 510(k) pathway on October 3, 2011 (K110318) for the treatment of chronic dermal wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds. Excellagen formulated collagen also represents a unique platform technology for the delivery of biologics for use in regenerative medicine applications. Prior research by Taxus Cardium and its collaborators has demonstrated biocompatibility and functionality of viral-based gene therapies and stem cell biologics when delivered in Excellagen. In addition to DNA- and stem cell-based biologics, Excellagen provides a potential enabling delivery platform for numerous therapeutic product classes, including small molecule drugs, peptides and anti-microbials.

The Excellagen manufacturing process includes steps by which purified full-length Type I collagen molecules are reassembled into collagen’s native, staggered fibrillar configuration. Scanning electron microscopy has demonstrated Excellagen’s 3-dimensional scaffold structure and histological analysis of Excellagen-treated dermal wounds demonstrates efficient infiltration with fibroblasts, and development of patent blood vessels. Excellagen is conveniently packaged in prefilled, ready to use syringes with accessory flexible applicator tips. Excellagen is topically applied in a thin layer directly to the entire wound surface, providing a structural scaffold for cellular infiltration and wound granulation. The flowable format allows immediate, intimate contact with the entire wound surface, including highly contoured wounds, and can also be easily applied to areas of undermining or tunneling. The wound is first prepared by performing sharp debridement using standard methods to remove debris and necrotic tissue, and then Excellagen should be applied in the presence of a small influx of blood. After application, the treated wound is overlaid with a non-adherent dressing. The treated wound (including non-adherent dressing) is left undisturbed for one week to allow Excellagen to promote new granulation tissue growth. If the wound is not completely healed, Excellagen may be reapplied weekly.

The FDA-approved instructions for use specify, “Surgically debride the wound bed using standard methods to ensure wound is free of debris and necrotic tissue. Allow a small influx of blood into the wound before applying Excellagen”. Taxus Cardium has demonstrated that Excellagen activates human platelets resulting in release of platelet-derived growth factor (PDGF). Excellagen’s ability to activate platelets is functional/biological evidence of its 3-dimensional fibrillar structure, as it has been demonstrated that this structure (as opposed to monomeric or denatured collagen) is required for effective platelet activation. Application of Excellagen in the presence of a small influx of blood cells and platelets likely contributes to its support of a favorable wound healing environment by triggering immediate, localized release of PDGF and other platelet-derived growth factors and cytokines, providing wound healing cues to the responsive cells exposed by debridement. However, platelet activation is not a requirement for Excellagen to provide benefits. As a wound heals and a bed of healthy granulation tissue develops, debridement becomes less necessary, but with continued application of Excellagen, its structural/functional benefits and support of a favorable healing environment are maintained.

Excellagen Clinical Evidence: Excellagen was studied in a multi-center, randomized, controlled, double-blinded Phase 2b study in patients with diagnosed diabetes (Type I or II) with non-healing ulcers of the lower extremity (with no bone or tendon exposed) that had failed prior therapy, that were present for at least 6 weeks, and were documented to be non-healing (≤ 30% decrease in ulcer area) during a 2-week run-in period under standard of care treatment (debridement, daily saline-moistened gauze, and off-loading). The study arms included Standard of Care (SOC; daily saline-moistened gauze dressing changes, offloading, and sharp debridement), and Excellagen applied only once (day 1) or twice (day 1 and week 4), with offloading and weekly outer dressing changes.

After the 12 week study period, 45% percent of the patients treated only once or twice with Excellagen (n=31) achieved complete wound closure. This was a 45% relative improvement over wounds treated with SOC therapy alone (n=16; 31% closure incidence). There was a 68% relative improvement with Excellagen for wounds achieving 90-100% area reduction during the 12-week evaluation period. In other words, 74% of wounds receiving only one or two applications of Excellagen achieved ≥90% area reduction compared with only 44% of patients receiving daily SOC. The improvement seen with Excellagen compared to SOC was even more dramatic for larger wounds (>3 cm2). In this case, 33% of wounds treated only once or twice with Excellagen achieved complete wound closure at 12 weeks whereas none of the SOC-treated wounds closed.

To assess the early response to Excellagen treatment, healing rates (reduction in wound radius, cm/week) were determined over the first two weeks following application. These analyses identified a statistically significant acceleration of healing with a single application of Excellagen compared to SOC. These accelerated healing rates were also reflected in the % area reductions at 2 weeks; Excellagen generated 97% and 105% relative improvements compared to SOC for area reductions of ≥50% and ≥75%, respectively. Therefore, the healing response following application of a single application of Excellagen was rapid and robust.

In the clinical study, Excellagen was applied to wounds only once or twice (with the second application four weeks after the first). Excellagen’s FDA clearance and the instructions for use suggest weekly application such that the accelerated healing and granulation tissue development observed in the Phase 2b study can be sustained, potentially further enhancing and accelerating the healing response. This schedule of weekly application has been followed in post-marketing use with positive reports of rapid, robust granulation tissue formation in chronic diabetic foot ulcers and pressure ulcers that have failed prior therapies.

Excellagen Competitive Position: Other marketed collagen-based products typically do not undergo the same degree of purification that Excellagen is subjected to, contain non-collagenous tissue components, are lyophilized or hydrolyzed (fragmented) and presented in a sheet configuration or a ground up powder requiring hydration before use. Many collagen-based wound care products undergo terminal sterilization (e.g. gamma irradiation or ethylene oxide), which can alter physical and structural properties of the collagen molecule by, for example, introducing artificial cross-links. Some products are also intentionally cross-linked with chemicals, which alters (slows) collagen biodegradation. Excellagen’s aseptic manufacturing process ensures that Excellagen retains the natural, non-artificially cross-linked, fibrillar form.

Excellagen’s ready-to use flowable format allows for greater versatility and ease of use than fix-structured, sheet-based products that require cutting to size, and fixation to the wound by suturing or stapling. Excellagen requires no product thawing or mixing before use. Furthermore, there is no product trimming or suturing required during application of Excellagen. The versatile, adherent gel formulation and the sterile, single use syringe applicator and tip allow for easy application, complete coverage, and intimate contact with wounds of varied etiology, shape, size, depth and surface contour.

We are now seeking to monetize Excellagen through sale of the technology and business unit or obtain strategic partners to market and sell Excellagen in the United States and elsewhere through multiple marketing channels. We have been in discussions with parties expressing interest in purchasing the business, however, as of the date of this report such discussions have not resulted in a completed monetization or strategic partnering transaction. We cannot guarantee that it will accept an offer to purchase the Excellagen business or that any such bona fide offer will be made on acceptable terms and conditions. Without a strategic partner, we do not plan to build inventory or establish an internal marketing and sales force to directly support the commercialization of Excellagen and have deferred the pursuit of CE mark certification for Excellagen.

Excellazome™ Advanced Wound Care Biologics Research

Activation Therapeutics, is developing plans to undertake research and preclinical studies to evaluate the toxicology and mechanism of action with respect to the use of Excellagen as a delivery platform for secreted extracellular vesicles (“Exosomes”), which carry factors that stimulate and augment wound healing.

Exosomes are small (30-100 nm diameter), cell-derived, lipid bilayer-encapsulated vesicles that are naturally secreted by most cell types. Exosomes are found in, and can be isolated from, almost all bodily fluids and the media of cultured cells. Exosome contents include lipids, proteins, nucleic acids, and soluble factors. First identified in 1983, only in recent years has the therapeutic potential of exosomes been recognized and investigated. They are now known to play a vital role in intercellular communication by delivering their contents to recipient cells, and triggering biologic responses.

In addition, exosomes are key secretory products of mesenchymal stem cells (MSC), and recently published preclinical research studies have demonstrated that MSC-derived exosomes can stimulate proliferation and migration of dermal fibroblasts, enhance angiogenesis, and accelerate wound healing in a diabetic mouse model. We believe that Excellagen could be a valuable delivery platform for exosomes in wound healing applications, by facilitating delivery and potentially augmenting the biological response to exosomes.

Based on this new and exciting field of research, in connection with (1) a strategic partnering transaction to market and sell Excellagen in the U.S., or (2) the sale of the Excellagen business unit (Activation Therapeutics), we currently plan to retain the exclusive rights to develop, market and sell an advanced biologic product extension utilizing Excellagen as a delivery platform for exosomes (Excellazome), to stimulate and augment wound healing beyond levels already observed with our Excellagen dermal matrix product.

Advancing the Excellazome biologic product concept to clinical and commercial readiness will require additional process engineering by exosome manufacturers to establish reproducible and scalable procedures that generate well-characterized end products that meet current Good Manufacturing Practices (cGMP) quality standards.

LifeAgain Insurance Solutions, Inc.

Our LifeAgain subsidiary has developed an advanced medical data analytics (ADAPT®) technology platform focused on developing new and innovative products for the life insurance and healthcare sectors. On April 4, 2015, Taxus Cardium entered into a license agreement with Shenzhen Qianhi Taxus Industry Capital Management Co., Ltd., a company affiliated with Shanxi Taxus Pharamaceuticals Co. Ltd., for the license of LifeAgain’s medical analytics technology to develop and commercialize survivable risk life insurance products in Greater China.

On August 11, 2015, Symetra Financial Corporation, our financial partner for LifeAgain initial product offering Blue Metric term life insurance program for men with prostate cancer, announced that it entered into a definitive merger agreement with Sumitomo Life Insurance Company pursuant to which Sumitomo Life will acquire all of the outstanding shares of Symetra. Following the transaction, Symetra advised the Company that it was discontinuing its partnership with LifeAgain. As a result, we are not currently offering the Blue Metric term life product.

LifeAgain plans to continue to seek opportunities for the application of medical analytics to commercialize “survivable risk” term life insurance for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards as well as other forms of survivable risk programs.

To Go Brands and Health Brands Collective.

On November 15, 2013, we sold the assets of our To Go Brands subsidiary to Healthy Brands Collective^® in exchange for an equity stake in Healthy Brands preferred stock which convertible into common stock representing approximately 4% of their fully-diluted common stock, and the assumption of approximately $300,000 of liabilities. Healthy Brands Collective^® is a private company that has acquired a portfolio of eight independent brand product platforms (prior to To Go Brands) including Cell-nique^®, Cherrybrook Kitchen^®, Yumnuts^®, Living Harvest/Tempt^®, Bites of Bliss^®, High Country Kombucha^® drinks and Organics European Gourmet Bakery^™ (formerly Dr. Oetker) natural and organic baking mixes.

At the time of the transaction Healthy Brands Collective, had announced plans for an initial public offering. Healthy Brands Collective has not completed any liquidity event. During the nine months ended September 30, 2015, we recorded $300,000 in impairment expense related to this investment. We are looking for opportunities to monetize our investment in Cell-nique, but do not have any arrangements or agreements in place at this time.

Critical Accounting Policies and Estimates

Our consolidated financial statements included under Item 1 in this report have been prepared in accordance with GAAP. The preparation of our financial statements in accordance with GAAP requires that we make estimates and assumptions that affect the amounts reported in our financial statements and their accompanying notes.

We have identified certain policies that we believe are important to the portrayal of our financial condition and results of operations, including obsolescence reserve for inventory, valuation of equity instruments, and impairment of long-lived assets. These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value. We base our estimates on our historical experience, industry standards, and various other assumptions that we believe are reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. An adverse effect on our financial condition, changes in financial condition, and results of operations could occur if circumstances change that alter the various assumptions or conditions used in such estimates or assumptions.

We record reserves for inventories that are obsolete or exceed anticipated demand or carried at an amount that exceeds market. In establishing such reserves, management considers historical sales of identical and/or similar goods, product development plans and expected market demand.

We calculate the value of equity compensation expense associated with the issuance of warrants and stock options using the Black-Scholes Option Model. Determining the appropriate fair value model and calculating the fair value of equity–based payment awards requires the input of a number of subjective assumptions including the expected stock volatility, the risk–free interest rate, the options expected life, the dividend yield on the underlying stock. The assumptions used in calculating the fair value of equity–based payment awards represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and the Company uses different assumptions, equity–based compensation could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If actual forfeiture rate is materially different from the estimates, the equity–based compensation could be significantly different from what the Company has recorded in the current period. If we were to undervalue our derivative liabilities or stock–based compensation expense we would understate the expense recognized in our consolidated statements of operation. Conversely if we were to overvalue our warrant and stock–based compensation expenses we would overstate the expense recognized in our consolidated statements of operations.

Our other significant accounting policies are described in the notes to our financial statements.

Results of Operations

For the Three Months Ended September 30, 2015 compared to the Three Months Ended September 30, 2014

Research and development expenses for the three months ended September 30, 2015 were $108,671 compared to $126,788 for the same period in 2014. The decrease of $18,117 was the result of a $25,000 increase in technology fees, a $32,551 increase in stock-based compensation expense offset by decreased costs of $ 29,862 related to production costs, a $42,750 decrease in personnel related costs and a $3,056 decrease in other research and development related costs.

Selling, general and administrative expenses for the three months ended September 30, 2015 were $1,081,189 compared to $586,414 for the same period in 2014. The increase of $494,775 was the result of a $669,672 increase in stock-based compensation offset by a $64,156 overall reduction in personnel and related costs, a $37,500 reduction in director fees, a $31,230 reduction in liability insurance related expenses, a $25,325 reduction of investor relations expenses and a $16,686 reduction of other selling, general and administration related expenses.

Interest expense for the three months ended September 30, 2015 was $2,106 compared to $28,600 for the same period in 2014. The decrease of $26,494 was the result of no interest expense charged on related party advances in 2015.

Net loss for the three months ended September 30, 2015 was $1,191,966 (including $703,384 of stock-based compensation) compared to a net loss of $1,441,802 (including $1,161of stock-based compensation) for the same period of 2014. The decrease of $249,836 in net loss was primarily a result of the change in operating and interest expenses described above offset by the $700,000 decrease in impairment loss on investment.

For the Nine Months Ended September 30, 2015 compared to the Nine Months Ended September 30, 2014

Research and development expenses for the nine months ended September 30, 2015 were $486,759 compared to $508,940 for the same period in 2014. The decrease of $22,181 was the result of a $180,680 reduction in personnel costs and related stock-based compensation, decreased costs of $129,085 related to clinical studies, outside consulting and production costs, a $10,465 reduction in other related research and development costs offset by a $50,000 increase in technology license fees, and a $248,049 increase in production and storage fees.

Selling, general and administrative expenses for the nine months ended September 30, 2015 were $2,449,745 compared to $2,580,009 for the same period in 2014. The decrease of $130,264 was the result a $460,371 reduction in personnel and related costs, and a $338,183 reduction of other selling, general and administrative expenses. Offsetting the reduction in expense were a $471,632 increase in stock-based compensation expense and an increase of $196,658 in professional services.

Interest expense for the nine months ended September 30, 2015 was $4,490 compared to $76,267 for the same period in 2014. The decrease of $71,777 was the result of no interest expense being charged on related party advances in 2015.

Net loss for the nine months ended September 30, 2015 was $3,240,994 (including $961,219 of stock-based compensation) compared to a net loss of $3,865,216 (including $508,444 of stock-based compensation) for the same period of 2014. The decrease in net loss was primarily a result of the decrease in operating and interest expenses described above and decrease of impairment loss on investment of $400,000.

Liquidity and Capital Resources

As of September 30, 2015, we had $18,217 in cash and cash equivalents. Our working capital deficit at September 30, 2015 was $3,370,406.

Net cash used in operating activities was $929,334 for the nine months ended September 30, 2015 compared to $2,433,134 for the nine months ended September 30, 2014. The decrease of $1,503,800 in net cash used in operating activities was due primarily to changes in operating assets and liabilities and non-cash expenses such as stock-based compensation.

We had no net cash used in investing activities for the nine months ended September 30, 2015 and 2014. At September 30, 2015 we did not have any significant capital expenditure requirements.

Net cash provided by financing activities was $730,818 for the nine months ended September 30, 2015 compared to $2,482,288 for the same period in 2014. For the nine month period ending September 30, 2015 the $600,000 net cash received from financing activities were payments from Shenzhen Qianhai Taxus Industry Capital Management Co. for an equity stake in either the Company or Angionetics and $130,818 net cash advances received from our Chief Executive Officer to cover ordinary Company expenses. For the nine month period ended September 30, 2014 net cash from financing activities was the result of two tranches of a common stock equity financing with Shanxi Taxus Pharamaceuticals Co. Ltd. The Company sold 3,045,104 shares of common stock for aggregate proceeds, net of issuance costs, of $1,829,999. In addition we received $652,289 of cash advanced from our Chief Executive Officer to cover ordinary Company expenses.

We anticipate that negative cash flows from operations will continue for the foreseeable future. We do not have any unused credit facilities. We intend to secure additional working capital through sales of additional equity and debt securities to finance our operations. As long as any shares of our Preferred Stock are outstanding, we have agreed that we will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, or incur any liens other than specified “Permitted Liens”.

Our principal business objectives are to advance the independent monetization and funding activities of our core products and technologies, with our Angionetics Inc. subsidiary being focused on the Generx® angiogenic gene therapy product candidate, and our Activation Therapeutics subsidiary being focused on the Excellagen® FDA-cleared wound care product and the joint clinical development of Excellagen product line extensions as an advanced biologic delivery platform for new and innovative wound healing therapeutics, and/or to complete alterative corporate transactions. If we fail to conclude such transaction in a timely manner or alternatively fail to generate sufficient cash from financing activities, we will not generate sufficient cash flows to cover our operating expenses.

On June 7, 2016, after the period covered by this report, Taxus Cardium and Angionetics entered into a Share Purchase Agreement with Pineworld Capital Limited an entity affiliated with Huapont Life Sciences Co. Ltd. a China-based pharmaceutical, and active pharmaceutical ingredient company (“Huapont”). Huapont is focused on the research and development of new and innovative healthcare products, and the manufacture, marketing and sale of leading pharmaceutical products, active pharmaceutical ingredients (known as APIs) and a portfolio of safe and effective agricultural herbicides (including NC16, NC34, NC36, NC125, NC201) serving the agricultural business throughout the U.S. and South American markets. Huapont’s pharmaceutical business includes dermatology products, cardiovascular products, anti-tuberculosis agents, autoimmune-related products and oncology-related products. Huapont’s API business involves the production and sale of bulk pharmaceutical chemicals, pharmaceutical intermediates and preparations of Western medicines, with current annual revenues of approximately $1.1 billion, and approximately 7,100 employees operating throughout Mainland China. Huapont is listed on the Shenzhen Stock Exchange (002004.SZ) and trades at a current market capitalization of approximately $3.0 billion.

Pursuant to the Share Purchase Agreement, Angionetics agreed to sell 600,000 shares of its newly authorized Series A Convertible Preferred Stock (the “Shares”) to the Huapont affiliate in exchange for $3,000,000 in cash. The Shares represent an initial 15% equity interest in Angionetics, resulting in a post-money valuation of $20.0 million for Angionetics, subject to certain anti-dilution protection described below.

Off-Balance Sheet Arrangements

As of September 30, 2015, we did not have any significant off-balance sheet debt nor did we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that have or are reasonably likely to have a material current or future effect on financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenue or expenses material to investors.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this item.

ITEM 4.

CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information is: (i) gathered and communicated to our management, including our principal executive and financial officers, on a timely basis; and (ii) recorded, processed, summarized, reported and filed with the SEC as required under the Securities Exchange Act of 1934, as amended.

Our management, with the participation of our Chief Executive Officer amd Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2015. Based on this evaluation, management concluded that our disclosure controls were not effective for their intended purposes described above as a result of a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected and corrected on a timely basis. For the year ended December 31, 2014, we noted the following material weaknesses in the operation of our internal controls as follows:

•

We did not maintain a sufficient complement of personnel with the appropriate level of accounting knowledge, experience and training in the application of GAAP commensurate with our financial reporting requirements; and

•

We did not maintain a sufficient complement of personnel to permit the segregation of duties among personnel with access to the Company’s accounting and information systems and controls.

Our management does not believe that the material weakness in internal controls has resulted in any inaccuracy or misstatement in the financial statements included in this report. We plan to remediate these material weaknesses by hiring additional qualified accounting personnel when the Company has the financial resources to support those expenses. However, these material weaknesses continued to exist during the quarterly period ended September 30, 2015.

There were no changes to our internal control over financial reporting during the quarterly period ended September 30, 2015 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

In addition to the risk factors described below, a number of risk factors that could materially affect our business, product candidates, financial condition and results of operations are disclosed and described in our 2014 Annual Report. You should carefully consider the risks described below and under Item 1A of our 2014 Annual Report, as well as the other information in our 2014 Annual Report, this report and other reports and documents we file with the SEC, when evaluating our business and future prospects. If any of the identified risks actually occur, our business, financial condition and results of operations could be seriously harmed. In that event, the market price of our common stock could decline and you could lose all or a portion of the value of your investment in our common stock.

Risks Related to Our Business and Industry

Angionetics will need additional funding to advance its clinical trial programs, launch and commercialize their lead product candidate.

Pharmaceutical product development, which includes research and development, pre-clinical and clinical studies and human clinical trials, is a time-consuming and expensive process that takes years to complete. We expect that Angionetics’s expenses will increase substantially as it advances Generx to late-stage clinical studies, and seeks regulatory approval.

If Angionetics, is unable to raise capital on acceptable terms in the future, the lack of funding may cause delay, diminish, or curtail certain operational activities, including research and development activities, clinical trials, sales and marketing, and other operations, in order to reduce costs and sustain the business, and such inability would have a material adverse effect on their business and financial condition.

We expect capital outlays and operating expenditures for Angionetics to increase over the next several years as it works to conduct clinical trials, commercialize products, and expand infrastructure. Angionetics will need to raise additional capital to, among other things:

•

Fund the completion of its U.S.-based Phase 3 AFFIRM clinical trial for Generx;

•

Fund additional clinical trials and preclinical trials for Generx as requested or required by regulatory agencies;

•

Fund clinical trials and preclinical trials for Generx in new indications;

•

Sustain commercialization of Generx or any other new product candidate;

•

Develop manufacturing capabilities, if any;

•

Increase sales and marketing efforts to drive market adoption and address competitive developments;

•

Acquire, license or in-license other product candidates;

•

Finance capital expenditures and our general and administrative expenses;

•

Develop new products;

•

Maintain, expand and protect its intellectual property portfolio, if any;

•

Add operational, financial and management information systems; and

•

Hire additional clinical, quality, scientific, and general and administrative personnel.

The present and future funding requirements of Angionetics will depend on many factors, including but not limited to:

•

The progress and timing of clinical trials;

•

The level of research and development investment required to maintain and improve our technology position;

•

Cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, if any;

•

Efforts to acquire or license complementary technologies or acquire complementary businesses;

•

Changes in product development plans needed to address any difficulties in commercialization;

•

Competing technological and market developments;

•

Changes in regulatory policies or laws that may affect our operations; and

•

Changes in physician acceptance or medical society recommendations that may affect commercial efforts.

There is a high rate of failure for drug candidates proceeding through clinical trials.

Generally, there is a high rate of failure for drug candidates proceeding through clinical trials. Angionetics may suffer significant setbacks in our clinical trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA or other regulatory authorities may disagree with our interpretation of the data. In the event that Angionetics obtains negative results from the AFFIRM Phase 3 clinical study or receives poor clinical results for other product candidates, or the FDA chooses to block progress of the trials due to potential Chemistry, Manufacturing and Controls (CMC) issues or other hurdles, or does not approve our Biologics License Application for Generx, Angionetics may not be able to generate sufficient revenue or obtain financing to continue operations, ability to execute on its current business plan will be materially impaired, our reputation in the industry and in the investment community would likely be significantly damaged and the price of our stock would likely decrease significantly.

Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates, or limit the scope of any approved label or market acceptance.

If Generx or any of our product candidates, prior to or after any approval for commercial sale, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:

•

Regulatory authorities may interrupt, delay or halt clinical trials;

•

Regulatory authorities may deny regulatory approval of our product candidates;

•

Regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a risk evaluation and mitigation strategy, or REMS;

•

Regulatory authorities may require the addition of labeling statements, such as warnings or contraindications or limitations on the indications for use;

•

We may be required to change the way the product is administered or conduct additional clinical trials;

•

We could be sued and held liable for harm caused to patients; or

•

Our reputation may suffer.

We may voluntarily suspend or terminate our planned clinical trials if at any time we believe that they present an unacceptable risk to participants or if preliminary data demonstrate that our product candidates are unlikely to receive regulatory approval or unlikely to be successfully commercialized. In addition, regulatory agencies, institutional review boards or data safety monitoring boards may at any time order the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any planned clinical trial of Generx or any other of our product candidates, the commercial prospects for that product will be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore, any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our product candidates and impair our ability to generate revenue from the commercialization of these products either by us or by our strategic alliance partners.

Risks Related to Our Capital Structure

Raising additional capital may cause dilution of our holdings in our subsidiaries or require our subsidiaries to relinquish certain intellectual property rights.

Angionetics may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, licensing arrangements and grants. To the extent that Angionetics raises additional capital through the sale of equity or convertible debt securities, our existing ownership interest in the subsidiary may be diluted, and the terms may include liquidation or other preferences that adversely affect our rights. Debt and receivables financings may be coupled with an equity component, such as warrants to purchase shares of our common stock, which could also result in dilution of our existing ownership. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on their ability to incur additional debt, limitations on their ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact their ability to conduct their business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to product candidates, or grant licenses on terms that are not favorable to us.

The conversion of our Series A Convertible Preferred Stock will result in substantial dilution to holders of our common stock.

At September 30, 2015, there were 1,116 shares of our Preferred Stock outstanding at a conversion price of $0.30 per share, and therefore convertible into 3,718,667 shares of common stock. The conversion price is subject to downward adjustment if we issue common stock or common stock equivalents at a price less than the then effective conversion price.

On July 22, 2015, we entered into an Exchange and Redemption Agreement with Sabby pursuant to which we agreed to reduce the conversion price on the Preferred stock to $0.30 per share. The Exchange and Redemption Agreement grants Taxus Cardium (1) a right to redeem any or all of the outstanding Preferred Stock for its Stated Value (approximately $1,000 per share) at any time during a 120 day period after the date of the Agreement, and (2) increases the limitation on indebtedness contained in the Certificate of Designation for the Preferred Stock to allow Taxus Cardium to borrow up to $250,000. As a result of the effective conversion price changing from $0.64 to $0.30 per share, the 1,176 shares of Preferred Stock outstanding are convertible to 3,918,667 shares of Taxus Cardium common stock, an additional 2,092,350 compared to before the conversion price change. The issuance of 3,918,667 common shares would increase the common stock outstanding from 12,975,044 shares as of September 30, 2015, to 16,893,711, an increase of 30%. As a result of the beneficial conversion feature related to the price change, the Company recorded a non-cash $627,705 charge as a deemed dividend on preferred stock in the accompanying condensed consolidated statements of operations.

On September 23, 2016, we entered into a second Exchange and Redemption Agreement with Sabby covering the 1,000 shares of Preferred Stock outstanding at the time. Under the terms of the Exchange and Redemption Agreement, Taxus Cardium agreed to reduce the conversion price at which shares of Preferred Stock can be converted to common stock to $0.18 per share. The Exchange and Redemption Agreement grants Taxus Cardium a right to redeem any or all of the outstanding Preferred Stock for its Stated Value (approximately $1,000 per share) at any time after the date of the Agreement until November 29, 2016. We entered into the agreement to increase our options for retiring the outstanding Preferred Stock and financing our continued business operations. As a result of the conversion price changing from $0.30 to $0.18 per share, the 1,000 shares of Preferred Stock outstanding are convertible to 5,554,667 shares of Taxus Cardium common stock, an additional 2,221,867 compared to before the conversion price change. A hypothetical conversion of all of the outstanding Preferred Stock into 5,554,667 common shares would increase the common stock outstanding from 12,975,044 shares as of September 30, 2015, to 18,529,711, an increase of 43%. The reduction of the conversion price under the Exchange and Redemption Agreement triggered an anti-dilution protection in 7,235,600 previously granted common stock purchase warrants not held by Sabby, resulting in an additional 4,823,733 warrant shares to be granted for a total of 12,059,333 common stock purchase warrant with anti-dilutive provisions outstanding. The exercise price per common share in these warrants remains unchanged as the original common stock purchase warrant, a weighted average price of $0.71.

Risks Related to Intellectual Property

If we do not obtain protection for our respective intellectual property rights, our competitors may be able to take advantage of our research and development efforts to develop competing products.

Our success, competitive position and future revenues depends in part on our ability to obtain and maintain patent protection for products, methods, processes and other technologies, to preserve trade secrets, to prevent third parties from infringing on their intellectual proprietary rights and to operate without infringing the proprietary rights of third parties.

The patent process is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining and defending patents. These risks and uncertainties include but are not limited to the following:

•

Patents may not be granted from patent applications.

•

Patents that have issued or will issue may be challenged, invalidated, or circumvented, or otherwise may not provide any competitive advantage.

•

Countries other than the United States may have less restrictive patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products.

•

Competitors, many of which have substantially greater resources than and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate their ability to make, use, and sell our potential products either in the United States or in international markets.

•

There may be significant pressure on the United States government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as a matter of public policy regarding worldwide health concerns.

In addition, the U.S. Patent and Trademark Office and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if our subsidiaries are able to obtain patents, the patents may be substantially narrower than anticipated.

In addition to patents, we also rely on trade secrets and proprietary know-how. Although we take measures to protect this information by entering into confidentiality and inventions agreements with employees, scientific advisors, consultants, and collaborators, we cannot provide any assurances that these agreements will not be breached, that we will be able to protect ourselves from the harmful effects of disclosure if they are breached, or that trade secrets will not otherwise become known or be independently discovered by competitors. If any of these events occurs, we otherwise lose protection for their trade secrets or proprietary know-how, the value of this information may be greatly reduced.

Intellectual property and trade secrets protection are important to the success of our business and prospects, and there is a substantial risk that such protections will prove inadequate.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibit index shows those exhibits filed with this report and those incorporated by reference:

EXHIBIT INDEX

Exhibit Number	Description	Incorporated By Reference To

4.1	Form of Warrant Agreement issued to directors and officers in February 2014.	Exhibit 4.1 of our Form 10-Q, filed with the Commission on May 15, 2014.

4.2	Certificate of Designation of Series A Convertible Preferred Stock of Angionetics Inc.	Exhibit 99.1 of our Current Report on Form 8-K filed with the Commission on July 11, 2016.

10.1	Strategic Cooperation Agreement dated February 21, 2014 between the registrant and Shanxi Taxus Pharmaceuticals Co., Ltd.	Exhibit 10.1 of our Current Report on Form 8-K filed with the Commission on March 4, 2014.

10.2	Securities Purchase Agreement dated February 21, 2014 between the registrant and Shanxi Taxus Pharmaceuticals Co., Ltd.	Exhibit 10.2 of our Current Report on Form 8-K filed with the Commission on March 4, 2014.

10.3	Exchange Redemption Agreement dated July 22, 2015 between the registrant and Sabby Healthcare Volatility Master Fund, Ltd.	Exhibit 10.1 of our Current Report on Form 8-K filed with the Commission on July 23, 2015.

10.4	Contribution Agreement dated June 6, 2016 between the registrant and Angionetics Inc.	Exhibit 10.2 of our Current Report on Form 8-K filed with the Commission on July 11, 2016.

10.5	Services Agreement dated June 6, 2016 between the registrant and Angionetics Inc.	Exhibit 10.3 of our Current Report on Form 8-K filed with the Commission on July 11, 2016.

10.6	Share Purchase Agreement dated June 7, 2016 among the registrant, Angionetics Inc. and Pineworld Capital Limited	Exhibit 10.1 of our Current Report on Form 8-K filed with the Commission on July 11, 2016.

10.7	Distribution and License Agreement dated June 7, 2016 between Angionetics Inc. and Pineworld Capital Limited	Exhibit 10.1 of our Current Report on Form 8-K filed with the Commission on July 11, 2016.

10.8	Exchange Redemption Agreement dated September 23, 2016 between the registrant and Sabby Healthcare Volatility Master Fund, Ltd.	Exhibit 10.1 of our Current Report on Form 8-K filed with the Commission on September 23, 2016.

31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer and Chief Financial Officer	Filed herewith.

32	Section 1350 Certification	Filed herewith.

101	The following financial statements and footnotes from the Taxus Cardium Pharmaceuticals Group, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 formatted in eXtensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Condensed Consolidated Financial Statements.	Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Taxus Cardium Pharmaceuticals Group, Inc., the registrant, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 27, 2016

	TAXUS CARDIUM PHARMACEUTICALS GROUP, INC.

	By:	/s/ CHRISTOPHER J. REINHARD
		Christopher J. Reinhard,
		Chief Executive Officer (Principal Executive Financial and Accounting Officer)

EX-31.1 2 crxm-ex311_10.htm EX-31.1 crxm-ex311_10.htm

Exhibit 31.1

Certification of Chief Executive Officer

Pursuant to

Rule 13a-14(a)/15d-14(a)

I, Christopher J. Reinhard, Chief Executive Officer of Taxus Cardium Pharmaceuticals Group, Inc., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Taxus Cardium Pharmaceuticals Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 27, 2016

		/s/ Christopher J. Reinhard
		Christopher J. Reinhard, Chief Executive Officer (Principal Executive Financial and Accounting Officer)

EX-32 3 crxm-ex32_11.htm EX-32 crxm-ex32_11.htm

Exhibit 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Taxus Cardium Pharmaceuticals Group, Inc., a Delaware corporation, does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015 of Taxus Cardium Pharmaceuticals Group, Inc. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Taxus Cardium Pharmaceuticals Group, Inc.

Date: October 27, 2016		/s/ Christopher J. Reinhard
		Christopher J. Reinhard, Chief Executive Officer
		(Principal Executive Financial and Accounting Officer)

The foregoing certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

EX-101.INS 4 crxm-20150930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure crxm:Tranche crxm:Employee 0000772320 2015-01-01 2015-09-30 0000772320 2016-10-27 0000772320 2015-09-30 0000772320 2014-12-31 0000772320 us-gaap:ConvertiblePreferredStockMember 2015-09-30 0000772320 us-gaap:ConvertiblePreferredStockMember 2014-12-31 0000772320 2015-07-01 2015-09-30 0000772320 2014-07-01 2014-09-30 0000772320 2014-01-01 2014-09-30 0000772320 2013-12-31 0000772320 2014-09-30 0000772320 crxm:ShenzhenQianhaiTaxusMember 2015-01-01 2015-09-30 0000772320 crxm:ShenzhenQianhaiTaxusMember 2015-04-04 0000772320 crxm:ShenzhenQianhaiTaxusMember 2015-04-03 2015-04-04 0000772320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000772320 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000772320 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000772320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000772320 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000772320 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000772320 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember us-gaap:ConvertiblePreferredStockMember crxm:SharePurchaseAgreementMember 2013-04-04 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember us-gaap:MaximumMember us-gaap:ConvertiblePreferredStockMember crxm:SharePurchaseAgreementMember 2013-04-03 2013-04-04 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember us-gaap:MaximumMember crxm:SharePurchaseAgreementMember 2013-04-03 2013-04-04 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-22 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-21 2015-07-22 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:MaximumMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-22 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:MinimumMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-22 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:HypotheticalConversionOnExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-22 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-09-30 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-22 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-21 2015-07-22 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-01-01 2015-09-30 0000772320 crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2015-07-01 2015-09-30 0000772320 crxm:TwoThousandFiveEquityIncentivePlanMember 2015-09-30 0000772320 crxm:DirectorsAndOfficersAndChiefMedicalAdvisorMember crxm:TwoThousandFiveEquityIncentivePlanMember 2014-02-27 2014-02-28 0000772320 crxm:DirectorsAndOfficersAndChiefMedicalAdvisorMember crxm:TwoThousandFiveEquityIncentivePlanMember 2014-02-28 0000772320 crxm:DirectorsAndOfficersAndChiefMedicalAdvisorMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-03-22 2015-03-23 0000772320 crxm:DirectorsAndOfficersAndChiefMedicalAdvisorMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-03-23 0000772320 crxm:NonQualifiedStockOptionMember us-gaap:DirectorMember 2015-03-22 2015-03-23 0000772320 crxm:DirectorsAndEmployeesMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-04-29 2015-05-01 0000772320 crxm:DirectorsAndEmployeesMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-05-01 0000772320 crxm:OneYearCliffVestingMember crxm:DirectorsAndEmployeesMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-04-29 2015-05-01 0000772320 crxm:ConsultantMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-05-07 2015-05-08 0000772320 crxm:ConsultantMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-05-08 0000772320 crxm:WarrantsVestedOverThreeQuartersMember crxm:ConsultantMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-05-07 2015-05-08 0000772320 crxm:ConsultantMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-01-01 2015-09-30 0000772320 crxm:ConsultantMember crxm:TwoThousandFiveEquityIncentivePlanMember 2015-08-03 2015-08-04 0000772320 2014-01-01 2014-12-31 0000772320 crxm:TwoThousandFiveEquityIncentivePlanMember 2015-01-01 2015-09-30 0000772320 us-gaap:WarrantMember 2014-12-31 0000772320 us-gaap:WarrantMember 2015-01-01 2015-09-30 0000772320 us-gaap:WarrantMember 2015-09-30 0000772320 us-gaap:WarrantMember 2014-01-01 2014-12-31 0000772320 crxm:BioRASILLCMember 2014-10-01 2014-10-31 0000772320 crxm:BioRASILLCMember 2015-09-30 0000772320 us-gaap:SubsequentEventMember crxm:AngioneticsIncMember crxm:ContributionAgreementMember 2016-06-06 0000772320 us-gaap:SubsequentEventMember crxm:AngioneticsIncMember crxm:ContributionAgreementMember 2016-06-05 2016-06-06 0000772320 us-gaap:SubsequentEventMember crxm:AngioneticsIncMember crxm:ContributionAgreementMember us-gaap:MinimumMember 2016-06-05 2016-06-06 0000772320 us-gaap:SubsequentEventMember us-gaap:ServiceAgreementsMember crxm:AngioneticsIncMember 2016-06-05 2016-06-06 0000772320 crxm:ScheringAGTechnologyTransferAgreementMember 2015-01-01 2015-09-30 0000772320 crxm:BayerPharmaAGMember us-gaap:SubsequentEventMember 2016-05-03 2016-05-04 0000772320 crxm:BayerPharmaAGMember us-gaap:SubsequentEventMember 2016-05-04 0000772320 crxm:FGF4BasedProductWithoutInfringePatentMember crxm:BayerPharmaAGMember us-gaap:SubsequentEventMember 2016-05-04 0000772320 crxm:OtherProductsWithoutInfringePatentMember crxm:BayerPharmaAGMember us-gaap:SubsequentEventMember 2016-05-04 0000772320 crxm:BayerPharmaAGMember us-gaap:SubsequentEventMember crxm:AngioneticsIncMember 2016-05-03 2016-05-04 0000772320 crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-06-05 2016-06-07 0000772320 country:CN crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-06-07 0000772320 exch:XSHE crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-06-07 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:HuapontLifeSciencesMember crxm:AngioneticsIncMember crxm:SharePurchaseAgreementMember us-gaap:SubsequentEventMember 2016-06-07 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:HuapontLifeSciencesMember crxm:AngioneticsIncMember crxm:SharePurchaseAgreementMember us-gaap:SubsequentEventMember 2016-06-05 2016-06-07 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:InitialTrancheMember crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-07-05 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:InitialTrancheMember crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-07-04 2016-07-05 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:SecondTrancheMember crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-06-07 0000772320 us-gaap:ConvertiblePreferredStockMember crxm:SecondTrancheMember crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember 2016-06-05 2016-06-07 0000772320 crxm:SecondTrancheMember crxm:HuapontLifeSciencesMember us-gaap:SubsequentEventMember crxm:AngioneticsIncMember 2016-09-27 2016-09-28 0000772320 crxm:AngioneticsIncMember us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2016-06-05 2016-06-07 0000772320 crxm:ShenzhenQianhaiTaxusMember us-gaap:SubsequentEventMember 2016-06-05 2016-06-07 0000772320 crxm:ShenzhenQianhaiTaxusMember us-gaap:SubsequentEventMember 2016-06-07 0000772320 crxm:PineworldCapitalLimitedMember us-gaap:SubsequentEventMember us-gaap:MaximumMember country:CN crxm:HuapontLifeSciencesMember 2016-06-07 0000772320 crxm:PineworldCapitalLimitedMember us-gaap:SubsequentEventMember us-gaap:MinimumMember country:CN crxm:HuapontLifeSciencesMember 2016-06-07 0000772320 crxm:PineworldCapitalLimitedMember country:CN crxm:HuapontLifeSciencesMember 2015-01-01 2015-09-30 0000772320 crxm:PineworldCapitalLimitedMember us-gaap:SubsequentEventMember country:CN crxm:HuapontLifeSciencesMember 2016-06-05 2016-06-07 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-09-23 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-09-22 2016-09-23 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember us-gaap:MaximumMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-09-23 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember us-gaap:MinimumMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-09-23 0000772320 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-10-27 0000772320 us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-09-23 0000772320 us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-10-27 0000772320 us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-10-26 2016-10-27 0000772320 us-gaap:SubsequentEventMember crxm:ExchangeAndRedemptionAgreementWithSabbyHealthcareVolatilityMasterFundLtdMember 2016-09-22 2016-09-23 0000772320 us-gaap:SubsequentEventMember 2016-10-27 0000772320 us-gaap:SubsequentEventMember us-gaap:ConvertiblePreferredStockMember 2016-10-27 0000772320 us-gaap:SubsequentEventMember us-gaap:SeriesAPreferredStockMember 2016-10-27 0000772320 us-gaap:SubsequentEventMember crxm:TwoThousandFiveEquityIncentivePlanMember 2016-10-27 0000772320 us-gaap:SubsequentEventMember crxm:TwoThousandFiveEquityIncentivePlanMember 2016-10-26 2016-10-27 0000772320 us-gaap:SubsequentEventMember 2016-10-26 2016-10-27 0000772320 us-gaap:SubsequentEventMember crxm:OfficeLeaseMember 2016-06-22 2016-06-23 0000772320 us-gaap:SubsequentEventMember crxm:OfficeLeaseMember 2016-06-23 0000772320 us-gaap:SubsequentEventMember us-gaap:ChiefExecutiveOfficerMember 2016-09-30 10-Q false 2015-09-30 2015 Q3 CRXM Taxus Cardium Pharmaceuticals Group Inc. 0000772320 --12-31 Smaller Reporting Company 13623544

18217

216733

19828

202957

38045

419690

8738

16414

300000

9989

46783

746093

1621284

1204302

967916

535251

819251

688433

3408451

2427986

3408451

2427986

600000

1298

1278

110739887

109150983

-114702853

-110834154

-3361668

-1681893

46783

746093

0.0001

40000000

1116

1176

1116

1176

1000

0.0001

200000000

12975044

12775044

12975044

12775044

108671

126788

486759

508940

1081189

586414

2449745

2580009

1189860

713202

2936504

3088949

-1189860

-713202

-2936504

-3088949

2106

28600

4490

76267

700000

300000

700000

-1191966

-1441802

-3240994

-3865216

627705

-1819671

-1441802

-3868699

-3865216

-0.14

-0.12

-0.30

-0.36

12902549

12261971

12818232

10730928

7677

10515

75000

961218

508444

-183129

-12312

-9989

-60000

416982

77465

432665

-11654

-929334

-2433134

130818

652289

600000

1829999

730818

2482288

-198516

49154

22489

71643

4490

3200

<div> Note 1—Organization and Liquidity Organization Taxus Cardium sp was incorporated in Delaware in December 2003. We are a holding company that operates a medical technologies portfolio of equity-based and potential royalty-driven investments as follows: (1) Angionetics, currently a majority-owned subsidiary focused on the late-stage clinical development and commercialization of Generx®, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease; (2) Activation Therapeutics a wholly owned subsidiary focused on the development and commercialization of the Excellagen® technology platform, the U.S. Food and Drug Administration (“FDA”)-cleared flowable dermal matrix for advanced wound care that has we believe broad potential applications as a delivery platform for small molecule drugs, proteins and biologics; (3) LifeAgain a wholly-owned subsidiary that has developed, an advanced medical data analytics (ADAPT®) technology platform focused on developing new and innovative products for the life insurance and healthcare sectors; and (4) a minority investment in Healthy Brands Collective, a functional food and nutraceutical company which acquired the Company’s To Go Brands® business. Formation of Angionetics Inc. Angionetics, a biotechnology company, incorporated by Taxus Cardium on April 13, 2015, was formed to create a separate company to develop Taxus Cardium’s Generx® cardiovascular gene therapy product candidate and technology platform. Our management team believes that the Generx® platform is undervalued in the current Taxus Cardium capital structure and believes that contributing the Generx® business to a separate entity will increase the opportunities for financing the continued development of Generx® through Phase III clinical trials. Taxus Cardium contributed to Angionetics all of the rights to our Generx® platform technology and will sell shares in Angionetics in order to raise capital based on a valuation of the Generx® platform technology for the purpose of funding the development and commercialization of Generx®. Our management also believes that funding for Generx® as a stand-alone company can be done at better pricing, resulting in less dilution and a “value unlock” for Taxus Cardium shareholders. The Company intends to retain a significant interest in Angionetics and return value to shareholders based on an increased value of its holdings through the independent external market valuation of Angionetics and the Generx® platform technology. Following the formation of Angionetics, our management team initiated a comprehensive review of the global Generx® regulatory and clinical dossier, and elected to primarily focus on the clinical advancement and registration of Generx® in the United States and China, which we believe to be the most dynamic medical markets in the world for new and novel breakthrough products such as the Generx® product candidate. As a result of this review, Angionetics now plans to focus on the late stage clinical and commercial development of Generx® in key target markets that include the U.S. and China. LifeAgain Activities On August 11, 2015, Symetra Financial Corporation (“Symetra”), our financial partner for LifeAgain initial Blue Metric term life insurance program for men with prostate cancer, announced that it entered into a definitive merger agreement with Sumitomo Life Insurance Company (“Sumitomo Life”) pursuant to which Sumitomo Life will acquire all of the outstanding shares of Symetra. Following the transaction, Symetra advised the Company that it was discontinuing its partnership with LifeAgain. LifeAgain plans to continue to seek opportunities for the application of medical analytics to commercialize “survivable risk” term life insurance for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards as well as other forms of survivable risk programs. On April 4, 2015, Taxus Cardium entered into a license agreement with Shenzhen Qianhi Taxus Industry Capital Management Co., Ltd., a company affiliated with Shanxi Taxus Pharamaceuticals Co. Ltd., for the license of LifeAgain’s medical analytics technology to develop and commercialize survivable risk life insurance products in Greater China.  Liquidity and Going Concern As of September 30, 2015, we had $18,217 in cash and cash equivalents. Our working capital deficit at September 30, 2015 was $3,370,406. We anticipate that negative cash flow from operations will continue for the foreseeable future. We have yet to generate positive cash flows from operations, and are essentially dependent on equity and debt funding to finance our operations. We do not have any unused credit facilities. As long as any shares of the Company’s Series A Convertible Preferred Stock are outstanding, we have agreed that we will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, or incur any liens other than specified “Permitted Liens”. Our history of recurring losses, and uncertainties as to whether the Company’s operations will become profitable, raise substantial doubt about our ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with the accounting principles generally accepted in the United States (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to continue its operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. The condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.   If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the condensed consolidated financial statements. We intend to secure additional working capital through sales of equity securities and debt to finance our operations, or the sale of certain equity interests in the Company businesses, technology platforms, products or product candidates and licensing agreements covering the marketing and sale of Excellagen and Generx in certain geographic markets and regions. On April 4, 2015, we entered into a binding term sheet with Shenzhen Qianhai Taxus Industry Capital Management Co., Ltd. (“Shenzhen Qianhai Taxus”), as a lead investor, to purchase an equity stake in Angionetics.  Under the terms of the agreement, Shenzhen Qianhai Taxus agreed to acquire 15% of Angionetics’ outstanding common stock for an aggregate purchase price of $3,000,000, payable in three tranches with the final payment due by May 31, 2015.  Shenzhen Qianhai Taxus paid $600,000, but did not complete the transaction.  See (Note 7)—Subsequent Events below.  The $600,000 investment has been recorded as Subscribed shares issuable – common stock.</div>

<div> Note 5—Stockholders’ Equity Preferred Stock Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. On April 4, 2013, we entered into a securities purchase agreement with Sabby Healthcare Volatility Master Fund, Ltd. (“Sabby”) to purchase up to 4,012 shares of our newly authorized Series A Convertible Preferred Stock (the “Preferred Stock”) for maximum proceeds of $4.0 million. The Preferred Stock was convertible into shares of our common stock at an initial conversion price of $0.6437 per share. In addition, the conversion price is subject to downward adjustment if we issue common stock or common stock equivalents at a price less than the then effective conversion price.  Sabby is limited to hold no more than 10% of Taxus Cardium’s issued and outstanding common stock at any time. As long as the Preferred Stock is outstanding, we have also agreed not to incur specified indebtedness without the consent of the holders of the Preferred Stock. These factors may restrict our ability to raise capital through equity or debt offerings in the future. On July 22, 2015, we entered into an Exchange and Redemption Agreement with Sabby relating to the 1,176 outstanding shares of Preferred Stock that remained outstanding at that time.  Under the terms of the Exchange and Redemption Agreement, we agreed to reduce the conversion price sp of the Preferred Stock to sp $0.30 per share. The Agreement grants Taxus Cardium (1) a right to redeem any or all of the outstanding Preferred Stock for its stated value (approximately $1,000 per share) at any time during a 120 day period after the date of the Agreement, and (2) increases the limitation on certain indebtedness contained in the Certificate of Designation for the Preferred Stock to allow Taxus Cardium to borrow up to $250,000. We entered into the Agreement to increase our options for retiring the outstanding Preferred Stock and financing our continued business operations. As a result of the effective conversion price changing from $0.64 to $0.30 per share, the 1,176 shares of Preferred Stock outstanding are convertible to 3,918,667 shares of Taxus Cardium common stock, an additional 2,092,350 compared to before the conversion price change. A hypothetical conversion of all of the outstanding Preferred Stock into 3,718,667 common shares would increase the common stock outstanding from 12,975,044 shares as of September 30, 2015, to 16,693,711, an increase of 29%.  As a result of such holder entering into this modification agreement, the holder received additional incremental shares, with a fair market value at the date of modification, totaling $627,705. This additional value was reflected as a deemed dividend in the statement of operations in arriving at net loss to common shareholders.. This reduction of the conversion price under the Exchange and Redemption Agreement triggered an anti-dilution protection in 3,485,908 previously granted common stock purchase warrants not held by Sabby, resulting in an additional 3,749,692 warrant shares to be granted for a total of 7,235,600 common stock purchase warrants with anti-dilutive provisions outstanding. The exercise price per common share in these warrants remains unchanged as the original common stock purchase warrant, a weighted average price of $0.71.  Stock-based compensation expense of $693,801 related to this anti-dilution provision was recorded during the three months ended September 30, 2015. Stock Options and Other Equity Compensation Plans We have an equity incentive plan that was established in 2005 under which 283,058 shares of the Company’s common stock have been reserved for issuance to employees, non-employee directors and consultants of the Company. At September 30, 2015, the following shares were outstanding and available for future issuance under the option plan:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Issuance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2005 Equity Incentive Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,250</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,808</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   On February 28, 2014, outside of the 2005 Equity Incentive Plan, we issued 1,457,100 common stock warrants to directors, officers and chief medical advisor. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.80 per share, which represented a 57% premium to the closing stock price on the date of issuance. The common stock warrants had a fair value of $0.34 per share and vested immediately. On March 23, 2015, outside of the 2005 Equity Incentive Plan, we issued 1,125,000 common stock warrants to directors, officers and chief medical advisor. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 216% premium to the closing stock price on the date of issuance. The warrants had a fair value of $0.10 per share and vested immediately. On March 23, 2015, we issued 10,000 non-qualified stock options to directors. The options were approved by our Board of Directors, have a seven year term and an exercise price of $0.19 per share, which equaled the closing stock price on the date of issuance. The stock options had a fair value of $0.14 per share. On May 1, 2015, outside of the 2005 Equity Incentive Plan, we issued 550,000 common stock warrants to directors and employees. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 20% premium to the closing stock price on the date of issuance. The warrants had a fair value of $0.37 per share and 300,000 vested immediately. 250,000 warrants have a 1 year cliff vesting. On May 8, 2015, outside of the 2005 Equity Incentive Plan, we issued 100,000 common stock warrants to a consultant. The warrants were approved by our Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 33% premium to the closing stock price on the date of issuance.  The commons stock warrants had a fair value of $0.41 per share.  40,000 warrants vested immediately, and the remaining 60,000 warrants vested over three quarters. On August 4, 2015, the consulting agreement was terminated and the remaining 60,000 unvested warrants cancelled per the terms of the consulting agreement and the common stock purchase warrant. The following is a summary of stock option and warrant activity under the 2005 Equity Incentive Plan as well as the warrants issued outside of the plan to employees and consultants, during the nine months ended September 30, 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options or <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, December 31,  2014</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,914,906</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.44</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.74</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,534,692</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled (unvested)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired (vested)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, September 30, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,353,848</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance exercisable, September 30, 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093,841</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of September 30, 2015, the Company had $50,732 of unvested stock-based compensation at fair value remaining to be expensed. As of September 30, 2015, there was no intrinsic value to the outstanding and exercisable options and warrants as their exercise price exceeded the market price of our common stock. The 2005 Equity Incentive Plan expired on October 20, 2015, ten years after its adoption, and we are no longer able to issue share or awards under that plan. All options or other awards issued under the 2005 Equity Incentive plan prior to its expiration remain outstanding in accordance with their terms. Warrants In addition to the warrants that we have issued as a form of compensation above, we have issued wattants to investors in connection with certain financing transactions.  The following table summarizes outstanding warrants as of September 30, 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, December 31, 2014</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">873,336</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.06</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,586</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.07</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, September 30, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716,750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.98</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercisable at September 30, 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.47</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of September 30, 2015, there was no intrinsic value to the outstanding and exercisable warrants as their exercise price exceeded the market value of our common stock.</div>

<div> Basis of Presentation The condensed consolidated financial statements contained in this report have been prepared in accordance with GAAP for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of our management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2015 and the results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future period. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Our accounting policies are described in the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and updated, as necessary, in this Quarterly Report on Form 10-Q.</div>

<div> Stock-Based Compensation Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award. Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">670,833</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703,384</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,409</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928,667</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457,035</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961,218</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508,444</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Investments We periodically reviews the carrying amount of our investments to determine whether the value is impaired or a write down may be necessary for other than temporary decline in value. During the nine months ended September 30, 2015, we recorded $300,000 in impairment expense related to our investment in Cell-nique (the owner of Healthy Brands Collective) as our management does not anticipate future cash flows from the investment.</div>

<div> Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">670,833</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703,384</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,409</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928,667</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457,035</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961,218</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508,444</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Accrued liabilities consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015 <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and benefits</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634,677</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,512</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology fees</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,739</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,739</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">967,916</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535,251</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> At September 30, 2015, the following shares were outstanding and available for future issuance under the option plan:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Issuance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2005 Equity Incentive Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,250</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,808</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following is a summary of stock option and warrant activity under the 2005 Equity Incentive Plan as well as the warrants issued outside of the plan to employees and consultants, during the nine months ended September 30, 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options or <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, December 31,  2014</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,914,906</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.44</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.74</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,534,692</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled (unvested)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired (vested)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, September 30, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,353,848</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance exercisable, September 30, 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093,841</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table summarizes outstanding warrants as of September 30, 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, December 31, 2014</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">873,336</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.06</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,586</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.07</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding, September 30, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716,750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.98</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercisable at September 30, 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.47</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

2003-12-22 3370406 Two-thirds

2015-04-04

0.15

3000000

600000

1.00

3718804

1826380

7353848 2434936

32551

670833

1161

703384

1161

32551

51409

928667

457035

961218

508444

634677

465512

187500

145739

69739

4012

4000000

0.6437

0.10

1176

0.30

1000

P120D 250000

0.64

0.30

3918667

3718667

2092350

12975044

16693711

0.29

627705

3485908 3749692 7235600 0.71

693801

283058

78250

204808

1457100 P10Y

0.80

0.57 0.34 1125000 P10Y

0.60

2.16 0.10

10000

P7Y

0.19 0.14 550000 P10Y

0.60

0.20 0.37 300000 250000

P1Y

100000 P10Y

0.60

0.33 0.41 40000 60000 2015-08-04 60000

1914906

5534692

60000

35750

7353848

7093841

2.44

0.67

0.60

24.11

1.02

1.04

P8Y8M27D

P9Y1M6D

P8Y10M6D

P8Y9M29D

50732

P10Y

2015-10-20

873336

156586

716750

716750 17.79 26.07 15.98 15.98 P1Y22D P5M19D P5M19D 0 0

500000

2000000

P12M 0.0999 0.70

4000000

10000000 Bayer Pharma AG agreed to the transfer of the Technology Transfer Agreement from Taxus Cardium to Angionetics. Accordingly, Angionetics has assumed the obligation for any milestone payment required to be paid to Bayer Pharma AG 0.05 0.04 0.025 0.02

1100000000

7100 3000000000

600000

3000000

0.15 20000000 2

200000

1000000

400000

2000000

0.15

The Shares are initially convertible on a one to one basis into Angionetics common stock.

600000

3000000

600000

0.10 0.05 quarterly P15Y The royalty payments commence on the first commercial sale and expire on the earlier of the termination of any patent or regulatory exclusivity in China or fifteen years after the first commercial sale. The term of the agreement continues (unless terminated for breach) until Huapont’s affiliate has no remaining payment obligations to Angionetics.

1000

0.18

1000

2016-11-29

0.30

0.18

5554667

2221867

946

5254444

13623544

18877988

0.39 7235600 4823733 12059333 0.71

13623544

945.80

5254444

78250

30.25

12099333

0.71

8554800

P38M

3500

3700

3800

3900

139800

1063865

EX-101.SCH 5 crxm-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Organization and Liquidity link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Advances From Related Party - Officer link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Organization and Liquidity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Advances From Related Party - Officer - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Stockholders' Equity - Schedule of Available Outstanding Shares for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stockholders' Equity - Summary of Stock Option and Warrant Activity under 2005 Equity Incentive Plan and Warrants Issued Outside of Plan to Employees and Consultants (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stockholders' Equity - Summary of Outstanding Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 6 crxm-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 crxm-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 crxm-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Prepaid expenses and other assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Investments Long Term Investments Other long-term assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Deficit Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Advances from related party – officer (net) Due To Officers Or Stockholders Current Total current liabilities Liabilities Current Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders’ deficit: Stockholders Equity [Abstract] Subscribed shares issuable – common stock Common Stock Shares Subscriptions Series A Convertible Preferred stock, $0.0001 par value; 40,000,000 shares authorized; issued and outstanding 1,116 at September 30, 2015 and 1,176 at December 31, 2014, with liquidation preferences of $1,000 Preferred Stock Value Outstanding Common stock, $0.0001 par value; 200,000,000 shares authorized; issued and outstanding 12,975,044 at September 30, 2015 and 12,775,044 at December 31, 2014, Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ deficit Stockholders Equity Total liabilities and stockholders’ deficit Liabilities And Stockholders Equity Series A Convertible Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Series A Convertible Preferred stock, shares authorized Preferred Stock Shares Authorized Series A Convertible Preferred stock, shares issued Preferred Stock Shares Issued Series A Convertible Preferred stock, shares outstanding Preferred Stock Shares Outstanding Series A Convertible Preferred stock, liquidation preference value Preferred Stock Liquidation Preference Value Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Operating expenses Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest expense Interest Expense Impairment loss on investment Impairment Of Investments Net loss Net Income Loss Deemed dividend on preferred stock Preferred Stock Dividends Income Statement Impact Net loss applicable to common stockholders Net Income Loss Available To Common Stockholders Basic Net loss per share – Basic and diluted Earnings Per Share Basic And Diluted [Abstract] Net loss per share – Basic and diluted Earnings Per Share Basic And Diluted Weighted average common shares outstanding Weighted Average Number Of Share Outstanding Basic And Diluted Warrants Issued Value As Payment For Note Payable Statement Of Cash Flows [Abstract] Cash Flows From Operating Activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Provision for obsolete inventory Inventory Write Down Stock-based compensation Share Based Compensation Impairment loss on investments Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other long-term assets Increase Decrease In Other Noncurrent Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash Flows From Financing Activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Cash advance from officer Proceeds From Related Party Debt Proceeds from subscribed shares issuable – common stock Proceeds From Issuance Of Common Stock Net proceeds from sales of preferred and common stock Proceeds From Issuance Or Sale Of Equity Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net increase (decrease) in cash Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Non-Cash Activity: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Warrants issued in settlement of accounts payable Warrants Issued Value As Payment For Note Payable Accounting Policies [Abstract] Organization and Liquidity Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Summary of Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Payables And Accruals [Abstract] Accrued Liabilities Accounts Payable And Accrued Liabilities Disclosure [Text Block] Related Party Transactions [Abstract] Advances From Related Party - Officer Related Party Transactions Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and contingencies Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Estimates Use Of Estimates Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Principles of Consolidation Consolidation Policy [Text Block] Preferred Stock Stockholders Equity Note Redeemable Preferred Stock Issue Policy Research and Development Research And Development Expense Policy Income Taxes Income Tax Policy [Text Block] Common stock purchase warrants. Common Stock Purchase Warrants Common Stock Purchase Warrants Policy [Text Block] Earnings (Loss) Per Common Share Earnings Per Share Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Investments Investment Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Summary of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of Available Outstanding Shares for Future Issuance Schedule Of Common Stock Outstanding Roll Forward Table [Text Block] Summary of Stock Option and Warrant Activity under 2005 Equity Incentive Plan and Warrants Issued Outside of Plan to Employees and Consultants Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Outstanding Warrants Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Business Combinations [Abstract] Organization, Nature Of Operations And Liquidity [Line Items] Organization, Nature Of Operations And Liquidity [Table] Organization Nature Of Operations And Liquidity [Table] Organization Nature Of Operations And Liquidity [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Shenzhen Qianhai Taxus [Member] Shenzhen Qianhai Taxus [Member] Shenzhen Qianhai Taxus [Member] Organization, Nature Of Operations And Liquidity [Line Items] Organization Nature Of Operations And Liquidity [Line Items] Incorporation date Entity Incorporation Date Of Incorporation Working Capital Deficit Working capital deficit Working Capital Deficit Majority of Shareholders Consent to Incur Indebtedness Other than Specified Permitted Indebtedness Majority of shareholders' consent to incur indebtedness other than specified permitted indebtedness Majority Of Shareholders Consent To Incur Indebtedness Other Than Specified Permitted Indebtedness Number Of Tranches Payable Business acquisition, date of agreement Business Acquisition Date Of Acquisition Agreement1 Acquired percentage of outstanding common stock Business Acquisition Percentage Of Voting Interests Acquired Business acquisition, purchase price Business Acquisition Equity Interest Issued Or Issuable Value Assigned Number of tranches payable Number Of Tranches Payable Payment for business acquisition Payments To Acquire Businesses Gross Inventory reserve percentage. Percentage of inventory reserve Inventory Reserve Percentage Incremental common shares attributable to stock options and warrants. Preferred stock converted into common stock Convertible Preferred Stock Shares Issued Upon Conversion Outstanding stock options and warrants Incremental Common Shares Attributable To Stock Options And Warrants Dilutive securities not included in calculation of loss per common share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development [Member] Research And Development Expense [Member] General and Administrative [Member] General And Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation Allocated Share Based Compensation Expense Impairment expense related to investment Accrued technology expense current. Accrued Liabilities Current [Abstract] Payroll and benefits Accrued Employee Benefits Current Technology fees Accrued Technology Expense Current Other Other Accrued Liabilities Current Total Related party transaction, expenses paid by chief executive officer Percentage of common stock issued and outstanding.. Stockholders Equity (Deficiency) [Line Items] Schedule of stockholders equity deficiency. Stockholders Equity [Table] Stockholders Equity [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Exchange and redemption agreement with Sabby healthcare volatility master fund Ltd. Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] Exchange And Redemption Agreement With Sabby Healthcare Volatility Master Fund Ltd [Member] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] Share purchase agreement. Share Purchase Agreement [Member] Share Purchase Agreement [Member] Range Range [Axis] Range Range [Member] Maximum [Member] Maximum [Member] Hypothetical conversion on exchange and redemption agreement with Sabby healthcare volatility master fund Ltd. Hypothetical Conversion on Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] Hypothetical Conversion On Exchange And Redemption Agreement With Sabby Healthcare Volatility Master Fund Ltd [Member] Minimum [Member] Minimum [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand five equity incentive plan. 2005 Equity Incentive Plan [Member] Two Thousand Five Equity Incentive Plan [Member] Title of Individual Title Of Individual [Axis] Relationship to Entity Title Of Individual With Relationship To Entity [Domain] Directors And Officers And Chief Medical Advisor [Member] Directors, Officers and Chief Medical Advisor [Member] Directors And Officers And Chief Medical Advisor [Member] Directors [Member] Director [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Non Qualified Stock Option [Member] Non-qualified Stock Options [Member] Non Qualified Stock Option [Member] Vesting Vesting [Axis] Vesting Vesting [Domain] One year cliff vesting. 1 Year Cliff Vesting [Member] One Year Cliff Vesting [Member] Directors and employees. Directors and Employees [Member] Directors And Employees [Member] Warrants vested over three quarters. Warrants Vested Over Three Quarters [Member] Warrants Vested Over Three Quarters [Member] Consultant. Consultant [Member] Consultant [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Proceeds from issuance of preferred stock Proceeds From Issuance Of Preferred Stock And Preference Stock Effective conversion price per share Preferred Stock Redemption Price Per Share Percentage of common stock issued and outstanding Percentage Of Common Stock Issued And Outstanding Preferred stock redemption period. Maximum limit on indebtedness. Additional convertible preferred stock shares issued upon conversion. Increase in common stock outstanding, percentage. Stated value per share for redemption Preferred Stock Liquidation Preference Preferred stock redemption period Preferred Stock Redemption Period Maximum limit on indebtedness Maximum Limit On Indebtedness Additional preferred stock converted into common stock Additional Convertible Preferred Stock Shares Issued Upon Conversion Increase in common stock outstanding, percentage Increase In Common Stock Outstanding Percentage Warrants granted to purchase common stock. Additional warrants granted to purchase common stock. Warrant outstanding to purchase common stock. Warrants weighted average exercise price. Granted common stock purchase warrants Warrants Granted To Purchase Common Stock Additional warrant shares to be granted Additional Warrants Granted To Purchase Common Stock Common stock purchase warrants outstanding with anti-dilutive provisions Warrant Outstanding To Purchase Common Stock Weighted average price of warrant Warrants Weighted Average Exercise Price Common stock reserved for issuance Common Stock Capital Shares Reserved For Future Issuance Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] EX-101.PRE 9 crxm-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 27, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	CRXM
Entity Registrant Name	Taxus Cardium Pharmaceuticals Group Inc.
Entity Central Index Key	0000772320
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,623,544

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 18,217	$ 216,733
Prepaid expenses and other assets	19,828	202,957
Total current assets	38,045	419,690
Property and equipment, net	8,738	16,414
Investments		300,000
Other long-term assets		9,989
Total assets	46,783	746,093
Current liabilities:
Accounts payable	1,621,284	1,204,302
Accrued liabilities	967,916	535,251
Advances from related party – officer (net)	819,251	688,433
Total current liabilities	3,408,451	2,427,986
Total liabilities	3,408,451	2,427,986
Commitments and contingencies
Stockholders’ deficit:
Subscribed shares issuable – common stock	600,000
Common stock, $0.0001 par value; 200,000,000 shares authorized; issued and outstanding 12,975,044 at September 30, 2015 and 12,775,044 at December 31, 2014,	1,298	1,278
Additional paid-in capital	110,739,887	109,150,983
Accumulated deficit	(114,702,853)	(110,834,154)
Total stockholders’ deficit	(3,361,668)	(1,681,893)
Total liabilities and stockholders’ deficit	46,783	746,093
Series A Convertible Preferred Stock [Member]
Stockholders’ deficit:
Series A Convertible Preferred stock, $0.0001 par value; 40,000,000 shares authorized; issued and outstanding 1,116 at September 30, 2015 and 1,176 at December 31, 2014, with liquidation preferences of $1,000	$ 0	$ 0

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	12,975,044	12,775,044
Common stock, shares outstanding	12,975,044	12,775,044
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred stock, par value	$ 0.0001	$ 0.0001
Series A Convertible Preferred stock, shares authorized	40,000,000	40,000,000
Series A Convertible Preferred stock, shares issued	1,116	1,176
Series A Convertible Preferred stock, shares outstanding	1,116	1,176
Series A Convertible Preferred stock, liquidation preference value	$ 1,000	$ 1,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses
Research and development	$ 108,671	$ 126,788	$ 486,759	$ 508,940
Selling, general and administrative	1,081,189	586,414	2,449,745	2,580,009
Total operating expenses	1,189,860	713,202	2,936,504	3,088,949
Loss from operations	(1,189,860)	(713,202)	(2,936,504)	(3,088,949)
Interest expense	(2,106)	(28,600)	(4,490)	(76,267)
Impairment loss on investment		(700,000)	(300,000)	(700,000)
Net loss	(1,191,966)	(1,441,802)	(3,240,994)	(3,865,216)
Deemed dividend on preferred stock	627,705		627,705
Net loss applicable to common stockholders	$ (1,819,671)	$ (1,441,802)	$ (3,868,699)	$ (3,865,216)
Net loss per share – Basic and diluted
Net loss per share – Basic and diluted	$ (0.14)	$ (0.12)	$ (0.30)	$ (0.36)
Weighted average common shares outstanding	12,902,549	12,261,971	12,818,232	10,730,928

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities
Net loss	$ (3,240,994)	$ (3,865,216)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	7,677	10,515
Provision for obsolete inventory		75,000
Stock-based compensation	961,218	508,444
Impairment loss on investments	300,000	700,000
Changes in operating assets and liabilities
Prepaid expenses and other assets	183,129	12,312
Other long-term assets	9,989	60,000
Accounts payable	416,982	77,465
Accrued liabilities	432,665	(11,654)
Net cash used in operating activities	(929,334)	(2,433,134)
Cash Flows From Financing Activities
Cash advance from officer	130,818	652,289
Proceeds from subscribed shares issuable – common stock	600,000
Net proceeds from sales of preferred and common stock		1,829,999
Net cash provided by financing activities	730,818	2,482,288
Net increase (decrease) in cash	(198,516)	49,154
Cash and cash equivalents at beginning of period	216,733	22,489
Cash and cash equivalents at end of period	18,217	71,643
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$ 4,490
Non-Cash Activity:
Warrants issued in settlement of accounts payable		$ 3,200

XML 15 R6.htm IDEA: XBRL DOCUMENT

Organization and Liquidity	9 Months Ended
Organization and Liquidity	Sep. 30, 2015
Accounting Policies [Abstract]
Organization and Liquidity	Note 1—Organization and Liquidity Organization Taxus Cardium sp was incorporated in Delaware in December 2003. We are a holding company that operates a medical technologies portfolio of equity-based and potential royalty-driven investments as follows: (1) Angionetics, currently a majority-owned subsidiary focused on the late-stage clinical development and commercialization of Generx®, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease; (2) Activation Therapeutics a wholly owned subsidiary focused on the development and commercialization of the Excellagen® technology platform, the U.S. Food and Drug Administration (“FDA”)-cleared flowable dermal matrix for advanced wound care that has we believe broad potential applications as a delivery platform for small molecule drugs, proteins and biologics; (3) LifeAgain a wholly-owned subsidiary that has developed, an advanced medical data analytics (ADAPT®) technology platform focused on developing new and innovative products for the life insurance and healthcare sectors; and (4) a minority investment in Healthy Brands Collective, a functional food and nutraceutical company which acquired the Company’s To Go Brands® business. Formation of Angionetics Inc. Angionetics, a biotechnology company, incorporated by Taxus Cardium on April 13, 2015, was formed to create a separate company to develop Taxus Cardium’s Generx® cardiovascular gene therapy product candidate and technology platform. Our management team believes that the Generx® platform is undervalued in the current Taxus Cardium capital structure and believes that contributing the Generx® business to a separate entity will increase the opportunities for financing the continued development of Generx® through Phase III clinical trials. Taxus Cardium contributed to Angionetics all of the rights to our Generx® platform technology and will sell shares in Angionetics in order to raise capital based on a valuation of the Generx® platform technology for the purpose of funding the development and commercialization of Generx®. Our management also believes that funding for Generx® as a stand-alone company can be done at better pricing, resulting in less dilution and a “value unlock” for Taxus Cardium shareholders. The Company intends to retain a significant interest in Angionetics and return value to shareholders based on an increased value of its holdings through the independent external market valuation of Angionetics and the Generx® platform technology. Following the formation of Angionetics, our management team initiated a comprehensive review of the global Generx® regulatory and clinical dossier, and elected to primarily focus on the clinical advancement and registration of Generx® in the United States and China, which we believe to be the most dynamic medical markets in the world for new and novel breakthrough products such as the Generx® product candidate. As a result of this review, Angionetics now plans to focus on the late stage clinical and commercial development of Generx® in key target markets that include the U.S. and China. LifeAgain Activities On August 11, 2015, Symetra Financial Corporation (“Symetra”), our financial partner for LifeAgain initial Blue Metric term life insurance program for men with prostate cancer, announced that it entered into a definitive merger agreement with Sumitomo Life Insurance Company (“Sumitomo Life”) pursuant to which Sumitomo Life will acquire all of the outstanding shares of Symetra. Following the transaction, Symetra advised the Company that it was discontinuing its partnership with LifeAgain. LifeAgain plans to continue to seek opportunities for the application of medical analytics to commercialize “survivable risk” term life insurance for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards as well as other forms of survivable risk programs. On April 4, 2015, Taxus Cardium entered into a license agreement with Shenzhen Qianhi Taxus Industry Capital Management Co., Ltd., a company affiliated with Shanxi Taxus Pharamaceuticals Co. Ltd., for the license of LifeAgain’s medical analytics technology to develop and commercialize survivable risk life insurance products in Greater China. Liquidity and Going Concern As of September 30, 2015, we had $18,217 in cash and cash equivalents. Our working capital deficit at September 30, 2015 was $3,370,406. We anticipate that negative cash flow from operations will continue for the foreseeable future. We have yet to generate positive cash flows from operations, and are essentially dependent on equity and debt funding to finance our operations. We do not have any unused credit facilities. As long as any shares of the Company’s Series A Convertible Preferred Stock are outstanding, we have agreed that we will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, or incur any liens other than specified “Permitted Liens”. Our history of recurring losses, and uncertainties as to whether the Company’s operations will become profitable, raise substantial doubt about our ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with the accounting principles generally accepted in the United States (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to continue its operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. The condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the condensed consolidated financial statements. We intend to secure additional working capital through sales of equity securities and debt to finance our operations, or the sale of certain equity interests in the Company businesses, technology platforms, products or product candidates and licensing agreements covering the marketing and sale of Excellagen and Generx in certain geographic markets and regions. On April 4, 2015, we entered into a binding term sheet with Shenzhen Qianhai Taxus Industry Capital Management Co., Ltd. (“Shenzhen Qianhai Taxus”), as a lead investor, to purchase an equity stake in Angionetics. Under the terms of the agreement, Shenzhen Qianhai Taxus agreed to acquire 15% of Angionetics’ outstanding common stock for an aggregate purchase price of $3,000,000, payable in three tranches with the final payment due by May 31, 2015. Shenzhen Qianhai Taxus paid $600,000, but did not complete the transaction. See (Note 7)—Subsequent Events below. The $600,000 investment has been recorded as Subscribed shares issuable – common stock.

XML 16 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2—Summary of Significant Accounting Policies

Basis of Presentation

Estimates

Fair Value of Financial Instruments

Principles of Consolidation

Preferred Stock

Research and Development

Income Taxes

Common Stock Purchase Warrants

Earnings (Loss) Per Common Share

Stock-Based Compensation

Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.

Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:

	For the Three Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	—
General and administrative		670,833		1,161
Total stock-based compensation	$	703,384	$	1,161

	For the Nine Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	51,409
General and administrative		928,667		457,035
Total stock-based compensation	$	961,218	$	508,444

Investments

Recent Accounting Pronouncements

XML 17 R8.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended

Sep. 30, 2015

Payables And Accruals [Abstract]

Accrued Liabilities

Note 3—Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2015 (unaudited)		December 31, 2014
Payroll and benefits	$	634,677	$	465,512
Technology fees		187,500		—
Other		145,739		69,739
Total	$	967,916	$	535,251

XML 18 R9.htm IDEA: XBRL DOCUMENT

Advances From Related Party - Officer	9 Months Ended
Advances From Related Party - Officer	Sep. 30, 2015
Related Party Transactions [Abstract]
Advances From Related Party - Officer	Note 4—Advances From Related Party - Officer Officers of the Company occasionally incur or advance expenses on behalf of the Company, which are subsequently reimbursed to the officers along with any associated costs. As of September 30, 2015 and December 31, 2014, $819,251 and $688,433, respectively, in net Company expenses incurred in the ordinary course of business that have been paid by or with cash advanced by the Company’s Chief Executive Officer.

XML 19 R10.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Stockholders' Equity

Note 5—Stockholders’ Equity

Preferred Stock

Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd.

Stock Options and Other Equity Compensation Plans

At September 30, 2015, the following shares were outstanding and available for future issuance under the option plan:

Plan

Outstanding

Available

for Issuance

2005 Equity Incentive Plan

78,250

204,808

	Number of Options or Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance outstanding, December 31, 2014		1,914,906		$	2.44		8.74
Granted		5,534,692		0.67			9.10
Cancelled (unvested)		(60,000	)	0.60			—
Expired (vested)		(35,750	)	$	24.11		—
Balance outstanding, September 30, 2015		7,353,848		$	1.02		8.85
Balance exercisable, September 30, 2015		7,093,841		$	1.04		8.83

As of September 30, 2015, the Company had $50,732 of unvested stock-based compensation at fair value remaining to be expensed.

As of September 30, 2015, there was no intrinsic value to the outstanding and exercisable options and warrants as their exercise price exceeded the market price of our common stock.

Warrants

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance outstanding, December 31, 2014		873,336		$	17.79		1.06
Warrants expired		(156,586	)		26.07
Balance outstanding, September 30, 2015		716,750		$	15.98		0.47
Warrants exercisable at September 30, 2015		716,750		$	15.98		0.47

As of September 30, 2015, there was no intrinsic value to the outstanding and exercisable warrants as their exercise price exceeded the market value of our common stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 20 R11.htm IDEA: XBRL DOCUMENT

Commitments and contingencies	9 Months Ended
Commitments and contingencies	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 6—Commitments and Contingencies In the course of our business, we are routinely involved in proceedings such as disputes involving goods or services provided by various third parties, which we do not consider likely to be material to the technology we develop or license, or the products we develop for commercialization, but which can result in costs and diversions of resources to pursue and resolve. In October 2014, we received a complaint filed by BioRASI LLC (“BioRASI”) in Broward County, Florida, seeking payments of approximately $0.5 million allegedly owed for services that BioRASI provided in connection with the Company’s clinical trial conducted in the Russian Federation. We are defending the action and have filed counterclaims. Although at September 30, 2015, the probable outcome of this matter cannot be determined, we believe that we have supportable defenses and any negative decision, if any, is expected to be insignificant. Accordingly, we have not recorded any provisions related to this matter.

XML 21 R12.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

Note 7—Subsequent Events

We have evaluated events that occurred subsequent to September 30, 2015 and through the date the condensed consolidated financial statements were issued.

Angionetics Formation

Schering AG Technology Transfer Agreement

Huapont Life Sciences Angionetics Financing Agreement

On June 7, 2016, Taxus Cardium and Angionetics entered into a Share Purchase Agreement with Pineworld Capital Limited an entity affiliated with Huapont Life Sciences Co. Ltd, a China-based pharmaceutical, and active pharmaceutical ingredient company (“Huapont”). Huapont is focused on the research and development of new and innovative healthcare products, and the manufacture, marketing and sale of leading pharmaceutical products, active pharmaceutical ingredients (known as APIs) and a portfolio of safe and effective agricultural herbicides (including NC16, NC34, NC36, NC125, NC201) serving the agricultural business throughout the U.S. and South American markets. Huapont’s pharmaceutical business includes dermatology products, cardiovascular products, anti-tuberculosis agents, autoimmune-related products and oncology-related products. Huapont’s API business involves the production and sale of bulk pharmaceutical chemicals, pharmaceutical intermediates and preparations of Western medicines, with current annual revenues of approximately $1.1 billion, and approximately 7,100 employees operating throughout mainland China. Huapont is listed on the Shenzhen Stock Exchange (002004.SZ) and trades at a current market capitalization of approximately $3.0 billion.

The Angionetics Shares have the following rights, privileges and preferences:

•

Dividends. Holders of the Shares are entitled to receive dividends as, when and if declared by the Angionetics board of directors on the Angionetics common stock, on an as-converted basis.

•

Generx License Agreement in Mainland China

Angionetics will be responsible for conducting the planned U.S.-based Phase 3 clinical program. Working in cooperation with researchers at Angionetics, Huapont’s affiliated entity has agreed to use commercially reasonable efforts to conduct clinical trials, make regulatory filings and take such other actions as may be necessary to commercialize Generx® in mainland China. Huapont’s affiliated entity will assume the costs associated with the commercial development of Generx® in mainland China.

FDA Approval of Phase 3 Clinical Trial for Generx

Status of Term Sheet with Dr. Reddy’s and Russian Generx Clinical Development Program

Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd.

Outstanding Capital Stock, Stock Options, and Warrants

Office Lease

Related Party Transactions

Officers of the Company occasionally incur or advance expenses on behalf of the Company, which are subsequently reimbursed to the officers along with any associated costs. As of September 30, 2016, $1,063,865 in net Company expenses incurred in the ordinary course of business have been paid by or with cash advanced by the Company’s Chief Executive Officer. This amount that has been advanced by the Chief Executive Officer is non-interest bearing.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation

Estimates

Fair Value of Financial Instruments

Principles of Consolidation

Preferred Stock

Research and Development

Income Taxes

Common Stock Purchase Warrants

Earnings (Loss) Per Common Share

Stock-Based Compensation

Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.

Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:

	For the Three Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	—
General and administrative		670,833		1,161
Total stock-based compensation	$	703,384	$	1,161

	For the Nine Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	51,409
General and administrative		928,667		457,035
Total stock-based compensation	$	961,218	$	508,444

Investments

Recent Accounting Pronouncements

XML 23 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses

Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:

	For the Three Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	—
General and administrative		670,833		1,161
Total stock-based compensation	$	703,384	$	1,161

	For the Nine Months Ended September 30,
	2015		2014
	(unaudited)
Research and development	$	32,551	$	51,409
General and administrative		928,667		457,035
Total stock-based compensation	$	961,218	$	508,444

XML 24 R15.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2015

Payables And Accruals [Abstract]

Summary of Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2015 (unaudited)		December 31, 2014
Payroll and benefits	$	634,677	$	465,512
Technology fees		187,500		—
Other		145,739		69,739
Total	$	967,916	$	535,251

XML 25 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Schedule of Available Outstanding Shares for Future Issuance

At September 30, 2015, the following shares were outstanding and available for future issuance under the option plan:

Plan

Outstanding

Available

for Issuance

2005 Equity Incentive Plan

78,250

204,808

Summary of Stock Option and Warrant Activity under 2005 Equity Incentive Plan and Warrants Issued Outside of Plan to Employees and Consultants

	Number of Options or Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance outstanding, December 31, 2014		1,914,906		$	2.44		8.74
Granted		5,534,692		0.67			9.10
Cancelled (unvested)		(60,000	)	0.60			—
Expired (vested)		(35,750	)	$	24.11		—
Balance outstanding, September 30, 2015		7,353,848		$	1.02		8.85
Balance exercisable, September 30, 2015		7,093,841		$	1.04		8.83

Summary of Outstanding Warrants

The following table summarizes outstanding warrants as of September 30, 2015:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance outstanding, December 31, 2014		873,336		$	17.79		1.06
Warrants expired		(156,586	)		26.07
Balance outstanding, September 30, 2015		716,750		$	15.98		0.47
Warrants exercisable at September 30, 2015		716,750		$	15.98		0.47

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 26 R17.htm IDEA: XBRL DOCUMENT

Organization and Liquidity - Additional Information (Detail)		9 Months Ended
	Apr. 04, 2015 USD ($) Tranche	Sep. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)
Organization, Nature Of Operations And Liquidity [Line Items]
Incorporation date		Dec. 22, 2003
Cash and cash equivalents		$ 18,217	$ 216,733	$ 71,643	$ 22,489
Working capital deficit		$ 3,370,406
Majority of shareholders' consent to incur indebtedness other than specified permitted indebtedness		Two-thirds
Shenzhen Qianhai Taxus [Member]
Organization, Nature Of Operations And Liquidity [Line Items]
Business acquisition, date of agreement		Apr. 04, 2015
Acquired percentage of outstanding common stock	15.00%
Business acquisition, purchase price	$ 3,000,000
Number of tranches payable \| Tranche	3
Payment for business acquisition	$ 600,000

XML 27 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accounting Policies [Abstract]
Percentage of inventory reserve		100.00%
Preferred stock converted into common stock	1,826,380	3,718,804	1,826,380
Outstanding stock options and warrants	2,434,936	7,353,848	2,434,936
Dilutive securities not included in calculation of loss per common share		0	0
Impairment expense related to investment	$ 700,000	$ 300,000	$ 700,000

XML 28 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 703,384	$ 1,161	$ 961,218	$ 508,444
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	32,551		32,551	51,409
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 670,833	$ 1,161	$ 928,667	$ 457,035

XML 29 R20.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities Current [Abstract]
Payroll and benefits	$ 634,677	$ 465,512
Technology fees	187,500
Other	145,739	69,739
Total	$ 967,916	$ 535,251

XML 30 R21.htm IDEA: XBRL DOCUMENT

Advances From Related Party - Officer - Additional Information (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Related party transaction, expenses paid by chief executive officer	$ 819,251	$ 688,433

XML 31 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($)								3 Months Ended		9 Months Ended
	Aug. 04, 2015	Jul. 22, 2015	May 08, 2015	May 01, 2015	Mar. 23, 2015	Feb. 28, 2014	Apr. 04, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Stockholders Equity [Line Items]
Preferred stock converted into common stock								3,718,804	1,826,380	3,718,804	1,826,380
Common stock, shares outstanding								12,975,044		12,975,044		12,775,044
Deemed dividend on preferred stock								$ 627,705		$ 627,705
Total stock-based compensation								703,384	$ 1,161	961,218	$ 508,444
Unvested stock-based compensation at fair value of remaining shares								50,732		50,732
Intrinsic value of options outstanding								0		0
Intrinsic value of options exercisable								0		0
Intrinsic value of warrants outstanding								0		0
Intrinsic value of warrants exercisable								$ 0		$ 0
Directors [Member] \| Non-qualified Stock Options [Member]
Stockholders Equity [Line Items]
Non-qualified stock options issued to directors					10,000
Options expiration term					7 years
Options exercise price per share					$ 0.19
Stock options fair value per share					$ 0.14
2005 Equity Incentive Plan [Member]
Stockholders Equity [Line Items]
Common stock reserved for issuance								283,058		283,058
Options expiration term										10 years
Plan expiration date										Oct. 20, 2015
2005 Equity Incentive Plan [Member] \| Directors, Officers and Chief Medical Advisor [Member]
Stockholders Equity [Line Items]
Common stock warrants, issued					1,125,000	1,457,100
Common stock warrants, term					10 years	10 years
Common stock warrants, exercise price					$ 0.60	$ 0.80
Common stock warrants, premium percentage					216.00%	57.00%
Common stock warrants, fair value per share					$ 0.10	$ 0.34
2005 Equity Incentive Plan [Member] \| Directors and Employees [Member]
Stockholders Equity [Line Items]
Common stock warrants, issued				550,000
Common stock warrants, term				10 years
Common stock warrants, exercise price				$ 0.60
Common stock warrants, premium percentage				20.00%
Common stock warrants, fair value per share				$ 0.37
Common stock warrants, vested				300,000
Vesting period				1 year
2005 Equity Incentive Plan [Member] \| Directors and Employees [Member] \| 1 Year Cliff Vesting [Member]
Stockholders Equity [Line Items]
Common stock warrants, vested				250,000
2005 Equity Incentive Plan [Member] \| Consultant [Member]
Stockholders Equity [Line Items]
Common stock warrants, issued			100,000
Common stock warrants, term			10 years
Common stock warrants, exercise price			$ 0.60
Common stock warrants, premium percentage			33.00%
Common stock warrants, fair value per share			$ 0.41
Common stock warrants, vested			40,000
Agreement termination date										Aug. 04, 2015
Common stock warrants cancelled	60,000
2005 Equity Incentive Plan [Member] \| Consultant [Member] \| Warrants Vested Over Three Quarters [Member]
Stockholders Equity [Line Items]
Common stock warrants, vested			60,000
Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized								40,000,000		40,000,000		40,000,000
Series A Convertible Preferred stock, shares outstanding								1,116		1,116		1,176
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Common stock, shares outstanding		16,693,711						12,975,044		12,975,044
Increase in common stock outstanding, percentage		29.00%
Granted common stock purchase warrants		3,485,908
Additional warrant shares to be granted		3,749,692
Common stock purchase warrants outstanding with anti-dilutive provisions		7,235,600
Weighted average price of warrant		$ 0.71
Total stock-based compensation								$ 693,801
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Effective conversion price per share		$ 0.30
Series A Convertible Preferred stock, shares outstanding		1,176
Stated value per share for redemption		$ 1,000
Preferred stock redemption period		120 days
Maximum limit on indebtedness		$ 250,000
Preferred stock converted into common stock		3,918,667
Additional preferred stock converted into common stock		2,092,350
Deemed dividend on preferred stock										$ 627,705
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Series A Convertible Preferred Stock [Member] \| Maximum [Member]
Stockholders Equity [Line Items]
Effective conversion price per share		$ 0.64
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Series A Convertible Preferred Stock [Member] \| Minimum [Member]
Stockholders Equity [Line Items]
Effective conversion price per share		$ 0.30
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Share Purchase Agreement [Member] \| Maximum [Member]
Stockholders Equity [Line Items]
Percentage of common stock issued and outstanding							10.00%
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Share Purchase Agreement [Member] \| Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized							4,012
Effective conversion price per share							$ 0.6437
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Share Purchase Agreement [Member] \| Series A Convertible Preferred Stock [Member] \| Maximum [Member]
Stockholders Equity [Line Items]
Proceeds from issuance of preferred stock							$ 4,000,000
Hypothetical Conversion on Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] \| Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock converted into common stock		3,718,667

XML 32 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Available Outstanding Shares for Future Issuance (Detail) - shares	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
2005 Equity Incentive Plan, Shares Outstanding	7,353,848	1,914,906
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
2005 Equity Incentive Plan, Shares Outstanding	78,250
2005 Equity Incentive Plan, Shares Available for Issuance	204,808

XML 33 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option and Warrant Activity under 2005 Equity Incentive Plan and Warrants Issued Outside of Plan to Employees and Consultants (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options or Warrants, Balance outstanding, Beginning Balance	1,914,906
Number of Options or Warrants, Granted	5,534,692
Number of Options or Warrants, Cancelled (unvested)	(60,000)
Number of Options or Warrants, Expired (vested)	(35,750)
Number of Options or Warrants, Balance outstanding, Ending Balance	7,353,848	1,914,906
Number of Options or Warrants, Exercisable, Ending Balance	7,093,841
Weighted Average Exercise Price, Balance outstanding, Beginning Balance	$ 2.44
Weighted Average Exercise Price, Granted	0.67
Weighted Average Exercise Price, Cancelled(unvested)	0.60
Weighted Average Exercise Price, Expired (vested)	24.11
Weighted Average Exercise Price, Balance outstanding, Ending Balance	1.02	$ 2.44
Weighted Average Exercise Price, Exercisable, Ending Balance	$ 1.04
Weighted Average Remaining Contractual Life (in years), Balance	8 years 10 months 6 days	8 years 8 months 27 days
Weighted Average Remaining Contractual Life (in years), Granted	9 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Exercisable, Ending Balance	8 years 9 months 29 days

XML 34 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Outstanding Warrants (Detail) - Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Balance outstanding, Beginning, Number of Warrants	873,336
Warrants expired, Number of Warrants	(156,586)
Balance outstanding, Ending, Number of Warrants	716,750	873,336
Warrants exercisable at September 30, 2015, Number of Warrants	716,750
Balance outstanding, Beginning, Weighted Average Exercise Price	$ 17.79
Warrants expired, Weighted Average Exercise Price	26.07
Balance outstanding, Ending, Weighted Average Exercise Price	15.98	$ 17.79
Warrants exercisable at September 30, 2015, Weighted Average Exercise Price	$ 15.98
Balance outstanding, Weighted Average Remaining Contractual Life (in years)	5 months 19 days	1 year 22 days
Warrants exercisable at September 30, 2015, Weighted Average Remaining Contractual Life (in years)	5 months 19 days

XML 35 R26.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - BioRASI LLC [Member] - USD ($)	1 Months Ended
	Oct. 31, 2014	Sep. 30, 2015
Loss Contingencies [Line Items]
Complaint filed seeking payments related to clinical trial	$ 500,000
Provision related to clinical trial		$ 0

XML 36 R27.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail)												9 Months Ended
Subsequent Events - Additional Information (Detail)	Oct. 27, 2016 USD ($) $ / shares shares	Sep. 28, 2016 USD ($)	Sep. 23, 2016 $ / shares shares	Jul. 05, 2016 USD ($) shares	Jun. 23, 2016 USD ($)	Jun. 07, 2016 USD ($) Employee Tranche shares	Jun. 06, 2016 USD ($)	May 04, 2016 USD ($)	Jul. 22, 2015 $ / shares shares	Apr. 04, 2015 USD ($)	Apr. 04, 2013 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) shares	Sep. 30, 2016 USD ($)	Dec. 31, 2014 shares	Sep. 30, 2014 shares
Subsequent Event [Line Items]
Preferred stock converted into common stock												3,718,804			1,826,380
Common stock, shares outstanding												12,975,044		12,775,044
Common stock shares sold												12,975,044		12,775,044
2005 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
2005 Equity Incentive Plan, Shares Available for Issuance												204,808
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Common stock, shares outstanding									16,693,711			12,975,044
Increase in common stock outstanding, percentage									29.00%
Granted common stock purchase warrants									3,485,908
Additional warrant shares to be granted									3,749,692
Common stock purchase warrants outstanding with anti-dilutive provisions									7,235,600
Weighted average price of warrant \| $ / shares									$ 0.71
Shenzhen Qianhai Taxus [Member]
Subsequent Event [Line Items]
Business acquisition, purchase price \| $										$ 3,000,000
Payment for business acquisition \| $										$ 600,000
Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized												40,000,000		40,000,000
Series A Convertible Preferred stock, shares outstanding												1,116		1,176
Series A Convertible Preferred stock, shares issued												1,116		1,176
Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Series A Convertible Preferred stock, shares outstanding									1,176
Effective conversion price per share \| $ / shares									$ 0.30
Stated value per share for redemption \| $ / shares									$ 1,000
Preferred stock converted into common stock									3,918,667
Additional preferred stock converted into common stock									2,092,350
Pineworld Capital Limited [Member] \| Huapont Life Sciences [Member] \| Mainland China [Member]
Subsequent Event [Line Items]
Royalty payment period												quarterly
Royalty description												The royalty payments commence on the first commercial sale and expire on the earlier of the termination of any patent or regulatory exclusivity in China or fifteen years after the first commercial sale. The term of the agreement continues (unless terminated for breach) until Huapont’s affiliate has no remaining payment obligations to Angionetics.
Minimum [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share \| $ / shares									$ 0.30
Maximum [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share \| $ / shares									$ 0.64
Schering AG Technology Transfer Agreement [Member]
Subsequent Event [Line Items]
Technology transaction fees \| $												$ 4,000,000
Milestone payment obligated as sale of product \| $												$ 10,000,000
Share Purchase Agreement [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized											4,012
Effective conversion price per share \| $ / shares											$ 0.6437
Share Purchase Agreement [Member] \| Maximum [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Proceeds from issuance of preferred stock \| $											$ 4,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares outstanding	13,623,544
Common stock shares sold	13,623,544
Common stock issuable upon the exercise of outstanding warrants	12,099,333
Average exercise price per share \| $ / shares	$ 0.71
Conversion price of warrants, amount \| $	$ 8,554,800
Subsequent Event [Member] \| Office Lease [Member]
Subsequent Event [Line Items]
Lease agreement term					38 months
Monthly base rent in year one \| $					$ 3,500
Monthly base rent in year two \| $					3,700
Monthly base rent in year three \| $					3,800
Monthly base rent in the final two months of the agreement \| $					3,900
Total base rent over the lease term \| $					$ 139,800
Subsequent Event [Member] \| 2005 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
2005 Equity Incentive Plan, Shares Available for Issuance	78,250
Weighted Average Exercise Price, Exercised \| $ / shares	$ 30.25
Subsequent Event [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Common stock, shares outstanding	18,877,988		13,623,544
Increase in common stock outstanding, percentage	39.00%
Granted common stock purchase warrants			7,235,600
Additional warrant shares to be granted			4,823,733
Common stock purchase warrants outstanding with anti-dilutive provisions			12,059,333
Weighted average price of warrant \| $ / shares			$ 0.71
Subsequent Event [Member] \| Shenzhen Qianhai Taxus [Member]
Subsequent Event [Line Items]
Business acquisition, purchase of number of shares						600,000
Business acquisition, purchase price \| $						$ 3,000,000
Payment for business acquisition \| $						600,000
Subsequent Event [Member] \| Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Series A Convertible Preferred stock, shares outstanding	945.80
Series A Convertible Preferred stock, shares issued	945.80
Subsequent Event [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Series A Convertible Preferred stock, shares outstanding	946		1,000
Effective conversion price per share \| $ / shares			$ 0.18
Stated value per share for redemption \| $ / shares			$ 1,000
Preferred stock redemption date			Nov. 29, 2016
Preferred stock converted into common stock	5,254,444		5,554,667
Additional preferred stock converted into common stock			2,221,867
Subsequent Event [Member] \| Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock converted into common stock	5,254,444
Subsequent Event [Member] \| Huapont Life Sciences [Member]
Subsequent Event [Line Items]
Revenues \| $						$ 1,100,000,000
Anti-dilution protection of equity interest						15.00%
Anti-dilution protection of post-money valuation \| $						$ 20,000,000
Number of tranches \| Tranche						2
Subsequent Event [Member] \| Huapont Life Sciences [Member] \| Series A Convertible Preferred Stock [Member] \| Initial Tranche [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized				200,000
Proceeds from issuance of preferred stock \| $				$ 1,000,000
Subsequent Event [Member] \| Huapont Life Sciences [Member] \| Series A Convertible Preferred Stock [Member] \| Second Tranche [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized						400,000
Proceeds from issuance of preferred stock \| $						$ 2,000,000
Subsequent Event [Member] \| Huapont Life Sciences [Member] \| Shenzhen Stock Exchange [Member]
Subsequent Event [Line Items]
Current market capitalization \| $						$ 3,000,000,000
Subsequent Event [Member] \| Huapont Life Sciences [Member] \| Mainland China [Member]
Subsequent Event [Line Items]
Number of employees \| Employee						7,100
Subsequent Event [Member] \| Chief Executive Officer [Member]
Subsequent Event [Line Items]
Related party transaction, net expenses paid by chief executive officer \| $													$ 1,063,865
Subsequent Event [Member] \| Angionetics Inc. [Member] \| Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Percentage of stock convertible at pro rata basis						15.00%
Preferred stock conversion basis						The Shares are initially convertible on a one to one basis into Angionetics common stock.
Subsequent Event [Member] \| Angionetics Inc. [Member] \| Huapont Life Sciences [Member] \| Second Tranche [Member]
Subsequent Event [Line Items]
Proceeds from issuance of preferred stock \| $		$ 2,000,000
Subsequent Event [Member] \| Angionetics Inc. [Member] \| Services Agreement [Member]
Subsequent Event [Line Items]
Facilities costs payment percentage							70.00%
Subsequent Event [Member] \| Pineworld Capital Limited [Member] \| Huapont Life Sciences [Member] \| Mainland China [Member]
Subsequent Event [Line Items]
Royalty expiration period						15 years
Subsequent Event [Member] \| Minimum [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share \| $ / shares			$ 0.18
Subsequent Event [Member] \| Minimum [Member] \| Pineworld Capital Limited [Member] \| Huapont Life Sciences [Member] \| Mainland China [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales						5.00%
Subsequent Event [Member] \| Maximum [Member] \| Series A Convertible Preferred Stock [Member] \| Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share \| $ / shares			$ 0.30
Subsequent Event [Member] \| Maximum [Member] \| Pineworld Capital Limited [Member] \| Huapont Life Sciences [Member] \| Mainland China [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales						10.00%
Subsequent Event [Member] \| Contribution Agreement [Member] \| Angionetics Inc. [Member]
Subsequent Event [Line Items]
Technology fee payable upon earlier of qualified initial public offering \| $							$ 2,000,000
Shares lock up period							12 months
Subsequent Event [Member] \| Contribution Agreement [Member] \| Minimum [Member] \| Angionetics Inc. [Member]
Subsequent Event [Line Items]
Percentage of outstanding capital stock							9.99%
Subsequent Event [Member] \| Bayer Pharma AG [Member]
Subsequent Event [Line Items]
Transfer agreement description								Bayer Pharma AG agreed to the transfer of the Technology Transfer Agreement from Taxus Cardium to Angionetics. Accordingly, Angionetics has assumed the obligation for any milestone payment required to be paid to Bayer Pharma AG
Royalty percentage on net sales								5.00%
Royalties to net sales of other product								4.00%
Subsequent Event [Member] \| Bayer Pharma AG [Member] \| FGF-4 Based Product Without Infringe Patent [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales								2.50%
Subsequent Event [Member] \| Bayer Pharma AG [Member] \| Other Products Without Infringe Patent [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales								2.00%
Subsequent Event [Member] \| Bayer Pharma AG [Member] \| Angionetics Inc. [Member]
Subsequent Event [Line Items]
Milestone payment obligated as sale of product \| $								$ 0
Sales under transfer agreement \| $								$ 0
Subsequent Event [Member] \| Share Purchase Agreement [Member] \| Angionetics Inc. [Member] \| Huapont Life Sciences [Member] \| Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized						600,000
Proceeds from issuance of preferred stock \| $						$ 3,000,000

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 101 195 1 false 36 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 100050 - Disclosure - Organization and Liquidity Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureOrganizationAndLiquidity Organization and Liquidity Notes 6 false false R7.htm 100060 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Accrued Liabilities Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureAccruedLiabilities Accrued Liabilities Notes 8 false false R9.htm 100080 - Disclosure - Advances From Related Party - Officer Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureAdvancesFromRelatedPartyOfficer Advances From Related Party - Officer Notes 9 false false R10.htm 100090 - Disclosure - Stockholders' Equity Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 10 false false R11.htm 100100 - Disclosure - Commitments and contingencies Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 11 false false R12.htm 100110 - Disclosure - Subsequent Events Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 12 false false R13.htm 100120 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 13 false false R14.htm 100130 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 14 false false R15.htm 100140 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureAccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureAccruedLiabilities 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquity 16 false false R17.htm 100160 - Disclosure - Organization and Liquidity - Additional Information (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetail Organization and Liquidity - Additional Information (Detail) Details 17 false false R18.htm 100170 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 18 false false R19.htm 100180 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAllocatedToResearchDevelopmentGeneralAndAdministrativeExpensesDetail Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses (Detail) Details 19 false false R20.htm 100190 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail Accrued Liabilities - Summary of Accrued Liabilities (Detail) Details 20 false false R21.htm 100200 - Disclosure - Advances From Related Party - Officer - Additional Information (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureAdvancesFromRelatedPartyOfficerAdditionalInformationDetail Advances From Related Party - Officer - Additional Information (Detail) Details 21 false false R22.htm 100210 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 22 false false R23.htm 100220 - Disclosure - Stockholders' Equity - Schedule of Available Outstanding Shares for Future Issuance (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAvailableOutstandingSharesForFutureIssuanceDetail Stockholders' Equity - Schedule of Available Outstanding Shares for Future Issuance (Detail) Details 23 false false R24.htm 100230 - Disclosure - Stockholders' Equity - Summary of Stock Option and Warrant Activity under 2005 Equity Incentive Plan and Warrants Issued Outside of Plan to Employees and Consultants (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndWarrantActivityUnder2005EquityIncentivePlanAndWarrantsIssuedOutsideOfPlanToEmployeesAndConsultantsDetail Stockholders' Equity - Summary of Stock Option and Warrant Activity under 2005 Equity Incentive Plan and Warrants Issued Outside of Plan to Employees and Consultants (Detail) Details 24 false false R25.htm 100240 - Disclosure - Stockholders' Equity - Summary of Outstanding Warrants (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingWarrantsDetail Stockholders' Equity - Summary of Outstanding Warrants (Detail) Details 25 false false R26.htm 100250 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.cardiumthx.com/20150930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 27 false false All Reports Book All Reports crxm-20150930.xml crxm-20150930.xsd crxm-20150930_cal.xml crxm-20150930_def.xml crxm-20150930_lab.xml crxm-20150930_pre.xml true true ZIP 43 0001564590-16-026389-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-026389-xbrl.zip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�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